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 The inability of the adult central nervous system (CNS) to regenerate combined with the 
progressive nature of many CNS pathologies poses a significant challenge in developing 
effective treatments. Biomaterials-based systems designed to deliver drugs and/or cells hold 
immense potential for moderating disease progression and promoting repair. Ideally, such 
systems should (1) allow minimally invasive administration, (2) provide localized and controlled 
delivery, and (3) protect the activity of their cargo for maximal therapeutic effect. Additionally, 
the ability to incorporate multiple treatment modalities is desirable as many CNS disorders are 
multi-faceted and complex in nature. Designing delivery systems that incorporate these features 
while simultaneously improving therapeutic outcomes, however, poses a significant challenge. 
This dissertation covers the formulation and application of polymer-based delivery systems for 
CNS repair, with specific focus given to the spinal cord and visual systems.  
We first demonstrated the biocompatibility and feasibility of a reverse thermal gel, 
poly(ethylene glycol)–poly(serinol hexamethylene urethane) (ESHU) for intraocular drug 
delivery. This injectable formulation is capable of sustaining the bevacizumab release in vivo, 
and ultimately may be used to reduce the injection frequency in patients with ocular diseases 
such as age-related macular degeneration. To emphasize the versatility of ESHU, it was 
combined with bone marrow stromal cells (BMSCs) for treatment of traumatic spinal cord injury 
in rats. ESHU improved BMSC survival 3.5-fold one week post-injury compared to BMSCs 
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injected in PBS, which was accompanied by increased nervous tissue sparing and functional 
recovery. Finally, we demonstrated the feasibility of a coacervate-based growth factor delivery 
system for treatment of traumatic spinal cord injury. Ultimately, we hope the coacervate may be 
used in combination to augment cell therapy and drive the development of innovative solutions 
to treat injuries for where there are no cures.   
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1.0  INTRODUCTION 
Current clinical strategies fall short in treating central nervous system (CNS) injury and disease 
in a manner that minimizes patient stress while improving outcomes. Major organs of the CNS 
such as the visual system, spinal cord and brain are isolated from the systemic circulation due to 
the impermeable blood brain barrier systems, which severely limit the bioavailability of 
conventional, intravenously administered drugs; oftentimes high doses must be given to achieve 
efficacy, introducing considerable risk for adverse side effects. As such, materials-based 
approaches are actively being pursued as they offer a way to deliver therapies locally, reducing 
toxicity and increasing efficacy. However, successful clinical translation of drug and cell 
delivery technologies has yet to be achieved in part due to the immense complexity of the CNS, 
and inhibitory environments in and around the affected region [1]. The visual system and spinal 
cord each have a set of unique challenges that must be considered when formulating biomaterials 
for regenerative therapies, and a complete understanding of these obstacles will help drive the 
development of effective interventions. 
 1 
1.1 OCULAR DRUG DELIVERY: INSIGHTS AND CHALLENGES  
1.1.1 Significance  
Efficient and effective ocular drug delivery is limited by the many barriers protecting the eye. 
While topical formulations such as eye drops and drug-eluting contact lenses have improved 
delivery to anterior targets (the cornea, iris, lens, anterior chamber, Figure 1), reaching the 
posterior segment of the eye (the retina, choroid, vitreous and optic nerve, Figure 1) poses a 
significant challenge. Posterior segment diseases such as age-related macular degeneration 
(AMD), retinitis pigmentosa, and diabetic retinopathy are among the leading causes of 
irreversible vision loss worldwide, affecting over 10 million people in the United States alone [2, 
3]. Current treatments involve repeated long-term administration of therapeutics at high doses, 
imposing significant burdens on both patients and hospitals, and increasing the risk of adverse 
side effects. In recent years, the rapid evolution of biomaterials technology for drug delivery 
applications and an increased understanding of the physiology and pharmacokinetic properties of 
the eye have enabled researchers to design and implement new strategies for targeting the 
posterior segment. These new approaches hold great promise in combating vision loss and have 
the potential to reduce healthcare costs and increase quality of life for patients worldwide. 
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 Figure 1. Anatomy of the eye and representation of ophthalmic drug delivery routes. Topical delivery 
via eye drops must diffuse across the anterior structures of the eye before reaching posterior targets (a).  
1.1.2 Barriers to Efficient Posterior Segment Delivery 
There are four principal routes employed to target drugs to the eye: topical, systemic, intraocular 
and periocular (e.g. subconjunctival and sub-Tenon injections) [4]. Each mode possesses 
strengths and weaknesses as summarized in Table 1, and the choice of delivery route is 
dependent on the target tissue and the drug being delivered. Topical administration (Figure 1, a) 
involves the use of eye drops, ophthalmic ointments, or gels; due to their ease of use and 
established safety, topical medications are the most commonly utilized formulation in ocular 
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treatment, especially for conditions affecting the anterior of the eye. However, much of the drug 
will be eliminated via the nasolacrimal duct, dilution by tears, and systemic absorption [5]. 
Additionally, the cornea presents an efficient barrier, composed of an epithelium with tight 
junctions which protect the eye from foreign materials [6]. Combined, these factors allow only 
about 5% of drug in an eye drop to permeate the cornea [4] and reach the aqueous humor, which 
necessitates frequent administration and results in poor patient compliance. With such limited 
permeation into the aqueous humor, the probability of therapeutic levels of topically 
administered drugs reaching the posterior of the eye is extremely low.  
Systemically administered therapies also have limited effect in the eye. The blood-ocular 
barriers limit diffusion of drugs to the posterior segment and separate the eye from the 
surrounding tissue. The blood-retinal barrier, which separates the neural retinal tissue from the 
blood supply, consists of two separating levels: the endothelium of the vasculature within the 
retina, and the retinal pigment epithelium (RPE), which separates the entire retina from the more 
highly vascularized and leaky choroidal layer (Figure 1) [7]. Together, these barriers regulate the 
diffusion of molecules into the posterior segment. Even when drugs are capable of penetrating 
the blood-ocular barriers, low blood flow to the region means that large doses must be 
administered, increasing the risk for adverse effects.   
Intravitreal injection offers the most direct access to the posterior segment (Figure 1b). 
However, this approach comes with inherent risks of endophthalmitis, retinal detachment, 
cataract, and uveitis [8, 9]. Intravitreally administered drugs often have rapid clearance and 
require frequent injections, imposing a significant burden on patients. Despite the risk of 
complications and inconvenience to the patient, intravitreal administration of anti-angiogenic 
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drugs for treatment of AMD remains the most common treatment modality, as it represents the 
best compromise among the administration routes.  
Periocular injection (such as subconjunctival or sub-Tenon injection, Figure 1c) provides 
an alternative to intravitreal injection that involves administration of therapeutic agents into 
layers of tissue surrounding the eye. This route is advantageous because drugs must cross the 
sclera, which is more permeable than the cornea [10] and therefore most therapies easily reach 
the choroid. However, efficient delivery to the retina remains a challenge as drugs must pass 
through the choroid where systemic absorption is a concern [11], then cross the RPE which is 
highly impermeable and can be considered the rate-limiting step in getting drugs to the retina 
[12].  
Table 1. Pros and cons of the different ocular drug delivery routes  
Administration Route Pros Cons 
Systemic (oral, intravenous) • Ease of administration 
• Poor posterior segment delivery 
• High doses required 
• Adverse side effects 
Topical (eye drops, ointments) 
• Ease of administration 
• Good anterior segment 
delivery 
• Poor posterior segment delivery 
• Rapid drug clearance  
Intravitreal • Good posterior segment delivery 
• Invasive 
• Short half-life → repeated injections 
• ↑ risk of side effects (retinal 
detachment, endophthalmitis) 
Periocular 
• Delivery to anterior and 
posterior segments 
• Less invasive than intravitreal 
• Poor penetration to retina 
• Risk of subconjunctival 
hemmorhage 
1.1.3 Bioengineering Strategies to Improve Ophthalmic Drug Delivery 
In order to circumvent the challenges surrounding drug delivery to the posterior segment, a 
number of biomaterials-based solutions have been investigated. While non-biodegradable 
implants have demonstrated superior drug delivery and therapeutic effect, the necessity of a 
second procedure to remove the device once all drug has been expended introduces the risk for 
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unnecessary complications. Therefore, most of the focus of current ophthalmic drug delivery 
research has been on biodegradable delivery systems. There are several systems in the clinical 
trial stage and a number more that show promise in preclinical studies.  
There are currently a handful of devices that are undergoing clinical trials in the United 
States. Ozurdex® (Allergan, Irvine, CA) is an injectable, rod-shaped implant composed of 
poly(lactic-co-glycolic acid) (PLGA) containing dexamethasone for treatment of macular edema 
and uveitis. This device releases dexamethasone for up to six months. In clinical investigations 
such as the HURON and GENEVA studies, Ozurdex ® implants significantly improved visual 
acuity in patients with posterior uveitis and macular edema for extended periods of time  [13-15]. 
Verisome ® (Icon Biosciences, Sunnyvale, CA) is an injectable drug delivery system that forms 
a spherule upon intravitreal injection. It is a versatile system that can deliver a broad range of 
therapeutic agents for up to one year, and is currently in clinical trials for delivery of 
triamcinolone acetonide to treat uveitis [16].   
A number of investigational implants also demonstrate promise for intravitreal delivery. 
Particulate formulations, for example, are a hot topic in ophthalmic drug delivery. Typically 
composed of PLGA, these formulations are capable of sustaining drug release for extended 
periods and demonstrate good biocompatibility [17-22]. Other materials studied include 
polyethylene glycol-coated cyanoacrylate nanoparticles to deliver tamoxifen, which significantly 
inhibited autoimmune uveoretinitis. When tamoxifen alone was delivered, the disease course was 
unaffected [23]. Chitosan nanoparticles have been studied as well and because they are naturally-
derived, possess inherent biocompatibility. However, rapid drug release (on the order of hours) 
will likely limit their use to short-term applications [24, 25]. Micro- and nano-particles are 
versatile and effective; however harsh preparation conditions may make them unsuitable for 
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unstable drugs, and intravitreal injection of particle suspensions may cause vitreous turbidity, 
affecting visual acuity.  
Liposomes, which are colloidal carriers composed of phospholipid layers ranging in size 
from 100-400 nm, are attractive due to their inherent biocompatibility and the ability to 
encapsulate both hydrophobic and hydrophilic drugs [26]. One study in rats found that when 
liposomes were used to deliver vasoactive intestinal peptide intravitreally, drug levels were 15 
times higher at 24h in eyes injected with liposome-delivered drugs, compared to drug alone [27]. 
Liposome-mediated delivery, while promising, is limited by a relatively short residence time, 
instability, and little control over drug release kinetics [28]. Encapsulation within polymer 
scaffolds or gels could further sustain release from liposomes; liposomal technology itself 
however would be likely most appropriate for treatment of conditions where the therapeutic 
window is a period of days to weeks.  
In situ-forming biodegradable gels are promising for intravitreal drug delivery as they can 
incorporate a multitude of drugs at varying doses. In some cases, microparticles and /or 
liposomes have been embedded within intraocular hydrogels to further prolong drug release [29, 
30]. Thermoresponsive hydrogels for intravitreal applications have been explored using non-
degradable poly(N-isopropylacrylamide) (PNIPAAM)-based hydrogels, as well as biodegradable 
poly(2-ethyl-2-oxazoline)-b-poly(ε-caprolactone)-b-poly(2-ethyl-2-oxazoline) gels, PEG gels, 
and chitosan/alginate polysaccharide gels [31-36]. These studies demonstrated that intravitreal 
injection of synthetic hydrogels caused no long-term (up to 2 months) changes to retinal 
function, intraocular pressure or histomorphology in rabbits. However, non-degradable 
PNIPAAM gels would require surgical removal. Biodegradable injectable hydrogel 
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formulations, while not extensively studied yet, are garnering more interest in the ophthalmology 
field as effective and practical drug delivery vehicles.  
In summary, the anatomy and physiology of the ocular system presents a unique set of 
challenges which limit effective treatment of ocular disease. An increased understanding of these 
barriers and rapidly evolving biomaterials technology are continuing to drive innovation in the 
field of ocular drug delivery such that a new standard of care can be achieved.  
1.2 BIOMATERIALS FOR SPINAL CORD REPAIR 
(Note: Portions of this chapter were published previously as: Gumera C & Rauck B, Wang Y. 
Materials for central nervous system regeneration: bioactive cues. Journal of Materials 
Chemistry 2011;21:7033-51 and is reproduced here with permission from the publisher.) 
 
Complete restoration of function in damaged nerves will significantly improve the lives of 
affected individuals and reduce the associated socioeconomic costs. In the U.S., it is estimated 
that 12,000 individuals sustain SCI each year, while more than 250,000 are already affected [37]. 
Patient care is estimated to cost more than $4 billion annually, a figure that does not include an 
additional $2.6 billion due to loss of productivity [38]. 
Injuries to the CNS are extremely difficult to reverse, with no current treatment capable 
of completely restoring function after traumatic injury. Depending on the severity of the injury, 
patients can experience respiratory complications, arrhythmias, blood clots, bladder and bowel 
problems, loss of sensation and paralysis [39, 40]. Currently the most commonly-used treatment 
for acute SCI is methylprednisolone, a synthetic glucocorticoid which is capable of reducing 
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inflammation and mitigating the progression of secondary injury [41]. However, to be effective 
high doses must be delivered systemically over prolonged time periods, introducing the risk of 
deleterious side effects. Intensive physical therapy can also help patients regain motor control, 
but is not always successful, especially in cases of severe trauma. As such, numerous alternative 
strategies are actively being researched including cell therapy, delivery of biomolecules, and 
implantation of biomaterial conduits [42-45]. Many of these bring hope that significant 
improvement in clinical outcome can be achieved in the near future for people suffering from 
serious nerve damages.  
Materials science and engineering is an integral part of many treatment methods under 
investigation. Such strategies are attractive because the complexity of CNS injury likely will 
necessitate a multi-faceted approach to regeneration. Materials of both synthetic and natural 
origin have been investigated for use as nerve guides, scaffolds, and drug and cell delivery 
vehicles [42-44, 46], with specific attention given to biodegradable materials. Non-degradable 
materials are impractical for use the CNS because they remain in the body indefinitely and can 
cause nerve compression as well as chronic inflammation, and require a second surgery for 
removal [47]. “Bioactive materials” – materials that improve the interaction with cells and 
tissues to enhance regeneration—will enable such combinatorial strategies [48-53]. Drug 
delivery, immobilization of ECM molecules, neurotransmitter-based materials, topographical 
cues and electrically-conducting materials are just a few examples of ways bioactivity can be 
imparted into materials (Table 1), and when utilized in combination may maximize the 
regenerative capacity of the CNS.  
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Table 2. Commonly used base materials may be combined with one or more bioactive cues to create 
bioactive materials to facilitate nerve regeneration. 
Base Material Bioactive Cues 
Naturally-derived Alginate 
Cellulose 
Chitosan 
Collagen 
Gelatin 
Fibrin 
Fibronectin 
Hyaluronan 
Keratin 
Silk 
Neurotrophic factors 
BDNF [54-56] 
EGF [57-59] 
FGF-1 [60]+ FGF-2 [57, 61] 
GDNF [62] 
NGF [63, 64] 
NT-3 [54, 65-71] 
 
ECM 
IKVAV [53, 56, 72-75] 
Laminin [50, 76, 77] 
RGD [51, 78, 79] 
RNIAEIIKDI [49] 
Tenascin-C [80, 81] 
YIGSR [72, 75, 82, 83]  
 
Neurotransmitters 
Acetylcholine [48] 
Dopamine [84] 
 
Other 
Chondroitinase ABC [65, 85] 
Electrical conduction [86-97] 
Methylprednisolone [98, 99]  
Poly-lysine [100-103] 
Contact guidance [104-110] 
Synthetic PCL 
PEG 
PGA, PLA, PLGA 
PGS 
PHB 
Self-assembling peptides 
1.2.1 Nervous System Biology 
1.2.1.1 Central Nervous System Structure and Organization 
Understanding the organization and biology of the nervous system is essential to 
formulating materials-based solutions to the challenges in nerve repair and regeneration. The 
CNS is composed of the brain and spinal cord and is responsible for conducting and interpreting 
signals between the brain and the body (Figure 2A). The PNS connects the CNS to the rest of 
the body. Though the two systems are intricately connected, each possesses a unique 
environment which results in drastically different responses to traumatic injury. This difference 
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is primarily attributable to the presence of Schwann cells in the PNS, which rapidly infiltrate the 
injury region and secrete growth-promoting cytokines [111], thus rendering the PNS more 
permissive for regeneration. The lack of Schwann cells, glial scar formation and the presence of 
growth inhibitory proteoglycans combine to generate an environment that is not conducive to 
regeneration in the CNS.   
There are two primary cell types in the CNS: neurons and glia. Neurons form specific 
contacts (synapses) with each other via their axons and dendrites to create neuronal networks. 
They secrete chemical messengers known as neurotransmitters at their synapses, which 
propagate electrical signals. Glial cells, such as astrocytes and oligodendrocytes, support, nourish 
and protect neurons. Oligodendrocytes form myelin sheaths around axons, which increase the 
conduction velocity of action potentials. Myelin contains approximately 70% lipids and 30% 
proteins [112] including myelin basic protein, myelin oligodendrocyte glycoprotein and myelin-
associated glycoprotein. Astrocytes promote oligodendrocyte myelinating activity, form the 
blood brain barrier, modulate neurotransmitter uptake and release, and maintain synaptic 
plasticity [113]. Microglial cells are also present in the CNS; they scavenge cell debris and 
secrete molecules that affect the immune and inflammatory response. In addition to supporting 
and nurturing neurons, glia also play an important role in the response to trauma and 
regeneration [114]. 
The tissue of the CNS is composed of two distinct regions: white matter and grey matter. 
White matter contains myelinated axon tracts and glial cells, and constitutes the communication 
networks between grey matter regions. The high lipid content of myelin gives this tissue its white 
appearance. The grey matter contains neuronal soma, glial cells and has a high capillary density. 
Its function is to route motor and sensory stimuli to interneurons via chemical synapse activity in 
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order to generate a response. Interneurons are cells which act as intermediaries between afferent 
neurons, which conduct impulses from the body toward the CNS, and efferent neurons, which 
conduct impulses away from the CNS towards the body. The tissue in both the brain and the 
spinal cord is covered by three layers of connective tissue: the dura mater, arachnoid mater, and 
pia mater, collectively referred to as the meninges. The subarachnoid space, between the 
arachnoid and pia mater, is filled with cerebral spinal fluid. The role of the meninges is to protect 
the CNS (Figure 2B). The ECM of the CNS is composed of hyaluronan, adhesive glycoproteins 
such as tenascin, laminin, netrin and reelin, and proteoglycans such as neurocan, versican and 
brevican. It serves to organize the CNS structure, guide axon growth and development, and store 
growth factors and cytokines. Additionally, the ECM modulates the mechanical properties of the 
CNS.  
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 Figure 2. Structure of the CNS. The spinal cord has four segments (C: cervical; T: thoracic; L: 
lumbar; S: sacral) which connect to discrete body regions. These segments connect to the brain via ascending 
(red) and descending (blue) pathways which transmit neural impulses to and from the brain, respectively (B).  
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1.2.1.2 Response to Injury 
Traumatic injury and degenerative diseases considerably alter the architecture and 
function of nerves. The regenerative ability of nervous tissue is highly influenced by glial cells, 
and permissive and non-permissive cues in the environment (Figure 3A). Specifically, the CNS 
has a limited capacity for spontaneous regeneration following disease or injury compared to the 
PNS, which may be attributed to the following: 1) mature neurons are post-mitotic and exist in a 
quiescent, non-dividing state; thus their intrinsic ability to regenerate declines with age; 2) a lack 
of trophic—or nutritional—support, which is provided by Schwann cells in the PNS [111]; 3) the 
presence of myelin debris and myelin-associated inhibitors [117]; and 4) the mechanical barrier 
imposed by the glial scar [118].   
Trauma to the CNS occurs in two phases. The primary acute stage is the immediate 
response to the mechanical insult. It is characterized by cell death at the injury epicenter, 
disruption of local blood flow, and inflammation. Axons traversing the injury region are severed, 
leaving connections distal to the injury site isolated from their soma. Disruption of cellular 
membranes causes leakage of intracellular contents and an increase in the extracellular Ca2+ 
concentration, which contributes to further cell death. Incomplete oxygen metabolism results in 
the generation of reactive oxygen species, lipid peroxidation and accumulation of endogenous 
toxins which in turn attack intact membranes on neighboring cells. Vascular damage and 
inflammation result in edema of the nervous tissue.  
The second, chronic phase of injury can span months to even years. Many of the events 
that occurred in the initial phase continue, resulting in atrophy of the damaged tissue. Reactive 
astrocytes and meningeal fibroblasts ultimately form a glial scar around the injury epicenter. 
Reactive astrocytes also secrete inhibitory molecules such as chondroitin sulfate proteoglycans. 
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Additionally, inhibitory myelin debris, such as myelin-associated glycoprotein and Nogo 
accumulate due to damaged myelin sheaths and oligodendrocyte death. The scar persists, serving 
to isolate remaining healthy tissue from damaged tissue. 
The cascade of events that occurs following trauma to the CNS is complex, illustrating 
how many factors inhibit axon regeneration. The glial scar presents a mechanical barrier to 
growing axons, while myelin debris and proteoglycans constitute biochemical barriers, as 
illustrated in Figure 3A. Utilization of bioactive materials to neutralize the inhibitory 
environment or encourage the growth of severed axons has enormous potential to improve neural 
regeneration (Figure 3B). More extensive information on the molecular and cellular events 
following nerve injury and therapeutic interventions in use can be found in several recent 
reviews [42, 44, 119-122].  
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 Figure 3. Following trauma, an influx of inflammatory cells and reactive astrocytes causes the lesion 
cavity to expand (A). Reactive astrocytes secrete inhibitory molecules, resulting in secondary damage to axons 
spared by the initial insult. This causes demyelination and increased concentrations of myelin-associated 
inhibitors. Combined, these factors inhibit regeneration [122]. (B) Biomaterials-based therapies can promote 
neural repair. They can be designed as conduits or lesion-filling scaffolds and can incorporate various 
bioactive factors which interact with surrounding cells and tissues to elicit a pro-regenerative response. 
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1.2.2 Materials Used in Nerve Regeneration 
A wide range of materials have been studied for use in the CNS, and can be classified based on 
their physico-chemical properties. These characteristics are cell-independent, and are the basis 
for defining three categories of base materials – natural, biodegradable synthetic, and bio-stable 
synthetic.  
1.2.2.1 Natural Materials 
Naturally-derived materials such as polysaccharides and glycosaminoglycans have been 
used extensively in tissue engineering applications. They possess good biocompatibility and may 
exhibit inherent bioactivity that can facilitate cell recognition and tissue integration. Moreover, 
this class of materials can be degraded by enzymes in the body. Examples of biodegradable 
natural materials include—but are not limited to—chitosan, collagen, fibronectin, fibrin, 
hyaluronic acid (HA) and Matrigel. 
Chitosan is a polysaccharide derived from the full or partial deacetylation of chitin, found 
in crustacean shells. By altering the degree of deacetylation and thus the amount of positive 
charges on chitosan, degradability and cell adhesiveness can be controlled. It exhibits pH 
sensitivity, forming a highly permeable gel at neutral pH [101]. Its ease of use and long in vivo 
lifetime make it appealing for nerve regeneration, where long recovery times are typically 
required. Moreover, culture of hippocampal neurons on chitosan membranes form extensive 
neural networks by 7 days, comparable to culture on poly-D-lysine-coated controls [123]. Recent 
evidence also suggests that chitosan itself is neuroprotective, as it has the capacity to seal 
damaged neuronal cell membranes, and limit the extent of lipid peroxidation and reactive oxygen 
species formation following injury [124, 125]. 
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Collagen has been widely explored for tissue engineering applications due to its 
abundance, biocompatibility, and ease of modification. Because it is present in the ECM, 
collagen is inherently cell-adhesive and is frequently used for three-dimensional cell culture 
studies [126, 127]. By varying the degree of cross-linking the strength, porosity and 
degradability of collagen can be controlled. Thus it is used in many different forms such as tubes, 
gels, membranes and coatings [83, 128-131]. For example a collagen-filament scaffold implanted 
into a rabbit SCI model resulted in axon growth through the injury epicenter and partial 
restoration of function as measured by the BBB test [132]. While BBB scores were significantly 
higher in treated groups, low scores overall (4.7±2.3, and 2.8±0.5 in controls, out of a total 
possible score of 21) suggest that functional recovery was limited to modest movement of hind 
limb joints. This indicates that substantial improvements need to be made to collagen to enhance 
its regeneration-promoting abilities.  
Mats made from the ECM glycoprotein fibronectin have been shown to be 
neuroprotective and permissive for axonal growth [133]. In addition to supporting repair, the 
mats integrated into spinal tissue with little cavitation, suggesting fibronectin may inhibit the 
progression of tissue damage. Much like collagen, fibronectin is present in the ECM and binds 
integrins on cell surfaces. It has been explored for use in CNS regeneration both as a base 
material and as a coating for other materials [130, 133]. Matrigel, a gelatinous mixture of 
proteins secreted by mouse sarcoma cells, forms a hydrogel at room temperature. It is composed 
of basal membrane extract and includes ECM proteins such as laminin, collagen IV, heparin 
sulfate proteoglycans and growth factors [134]. It is valuable as an ECM mimicking matrix to 
study 3-D neural cell culture. Matrigel was also used as a cell delivery vehicle in order to 
improve the viability of human neural stem cells implanted in a canine model of SCI [135]. 
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Though Matrigel is a powerful research tool, its tumorigenic origin will likely present significant 
regulatory challenges for translation to human applications.  
Fibrin is another material investigated for CNS regeneration. Because it is a natural 
wound-healing matrix, it can be autologously-obtained, and has tailorable mechanical and 
degradation properties. Implanting fibrin scaffolds in rats two weeks after SCI resulted in 
decreased glial scarring and enhanced axon sprouting compared to untreated controls [136]. The 
most significant work done using fibrin in the CNS is that of Sakiyama-Elbert and colleagues, 
who have modified fibrin into a versatile and effective drug delivery system (See ‘1.2.3.1 
Neurotrophins’) [65, 66, 69-71, 136, 137].  
Hyaluronic acid is a long, negatively-charged glycosaminoglycan, and a major 
component of CNS ECM. A linear copolymer of D-glucuronic and N-acetyl-D-glucosamine, HA 
has been frequently modified with bioactive agents for drug delivery to the CNS. It has been 
shown to promote angiogenesis at low molecular weights and inhibit glial scarring at high 
molecular weights [51]. In vitro, HA hydrogels cross-linked with PEG promoted 50% longer 
neurite outgrowth from DRGs compared to fibrin gels [138]. Additionally, Shoichet and 
colleagues [139, 140] developed an injectable blend of HA and methylcellulose in order to create 
a fast-gelling drug delivery system, which will be discussed further in Section 1.2.3.2.  
Agarose, a polysaccharide obtained from agar, has also been studied extensively for CNS 
regeneration applications. Because it does not evoke a significant inflammatory or immune 
response, integrates well with CNS tissue and is inherently non-cell adhesive, agarose is useful 
for guided axon growth. It has been fabricated into nerve guidance scaffolds with uniaxial 
channels through both freeze-drying and templating techniques [141, 142]. It has also been used 
as a delivery system for therapeutic biomolecules such as methylprednisolone and chondroitinase 
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ABC [85, 99]. However, agarose is not biodegradable; thus its ultimate clinical use may be 
limited. This list of materials is not meant to be exhaustive, but provides an idea of the 
contribution that naturally-derived biomaterials make to the field of CNS regeneration. Their 
versatility enables them to be used in a variety of forms, as base materials and as modifications 
or coatings of other base materials.  
1.2.2.2 Biodegradable Synthetic Materials 
Batch-to-batch variability and the potential for disease transmission with mammalian-
derived materials are two challenges faced when using natural materials. In these aspects, 
synthetic materials are advantageous because stringent synthesis and manufacturing protocols 
avoid these complications. Generally, synthetic materials can be processed into a variety of 
physical structures. Unlike natural materials, however, synthetic materials do not have inherent 
bioactive cues, and need modification to possess bioactivity. Biodegradable synthetic materials 
can be degraded, absorbed or remodeled by the body, ideally being replaced by new tissue as the 
nerve grows to minimize physical interference with the regenerating nerve. Both the material and 
its degradation products must be non-toxic. The biodegradable synthetic materials described here 
include PGA, PLA, PLGA, PCL, PHB, PGS and synthetic peptide amphiphiles. 
PGA, PLA and their copolymers (PLGA) belong to the family of poly(α-hydroxyacids) 
that have been used in tissue engineering applications due to their biocompatibility, 
biodegradability and wide availability. The Neurotube, composed of PGA and manufactured by 
Synovis, was the first biodegradable synthetic peripheral nerve guide approved by the FDA for 
clinical use [143]. Moreover, PLGA has been approved by the FDA for use in a wide range of 
therapies. It is especially beneficial for drug delivery because its degradation rate is easily 
controlled by varying the ratio of glycolic acid to lactic acid. It has also been used to study the 
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effects of mechanical properties, topography, and drug and cell delivery on neurite outgrowth 
[144-152]. 
Polycaprolactone (PCL), also a component of several FDA-approved devices, has also 
been used in the CNS. Compared to PLGA, PCL degrades more slowly and results in fewer 
acidic degradation products. It has been shown to elicit a weaker inflammatory response—as 
demonstrated by fewer activated macrophages and astrocytes—than PLGA when implanted in 
the rat brain [146]. PCL is easily manipulated into a variety of shapes and sizes, and is 
commonly used for studying the effect of material topography on neurite outgrowth [104-106, 
110, 153, 154]. 
Polyhydroxybutyrate (PHB) and poly(glycerol sebacate) (PGS) have been studied for 
nerve regeneration, albeit less extensively, with good biocompatibility and promising results 
[155, 156]. PHB is a polyester that is synthesized in microorganisms under nutrient deficiency, 
and can be produced commercially using a fermentation process [157]. It exhibits good 
biocompatibility and is capable of supporting axon growth in vivo [155]. PGS is an elastomer 
that degrades by surface erosion and possesses mechanical properties close to those of nervous 
tissue. PGS exhibits good biocompatibility in the PNS, where it elicits significantly less 
inflammation and fibrosis than PLGA [156, 158]. Though PGS hasn’t been used in CNS injury 
models, its properties make it a viable candidate for future study. 
Peptide amphiphiles are synthetic molecules containing hydrophobic and hydrophilic 
domains, enabling them to self-assemble into cylindrical nanofibers when the ionic strength of 
the environment changes [74, 159]. These molecules were designed such that they display a 
bioactive peptide sequence at their hydrophilic end. Peptide amphiphiles form a gel-like 3-D 
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network and have been used both in vitro and in vivo to study the effect of the laminin peptide 
IKVAV on neural growth and repair (See 2.3.3 ECM Peptides).   
Most synthetic materials have little to no inherent biological activity. Therefore current 
studies using synthetic biodegradable materials involve various types of coatings and/or 
modifications – either with ECM peptides, growth factors or other therapeutic agents – to impart 
bioactivity to the material and make it more permissive for neuronal growth. In the following 
sections, we will highlight select modification strategies in order to elucidate the critical role 
bioactive cues play in nerve regeneration.  
1.2.3 Materials-Based Delivery of Bioactive Agents 
The failure of cells to activate regeneration-associated genes and the accompanying lack of 
neurotrophic support are major factors that hinder nerve repair [160, 161]. Addition of 
neurotrophins, antibodies or other therapeutic agents after nerve injury can provide 
neuroprotection and enhance axonal growth. For example, injections of BDNF or NT-3 after SCI 
significantly increase the survival of rubrospinal neurons [162] and promote axonal growth into 
the distal spinal cord [54]. Other neurotrophins studied include neurotrophin-4/5, GDNF, and 
NGF, all of which can preserve CNS tissue [42]. Additionally, NT-3 and BDNF stimulate 
oligodendrocyte proliferation and increase myelination [163]. Antibodies and other therapeutic 
agents, such as anti-inflammatory drugs and glial scar digesting enzymes can also suppress the 
progression of secondary damage and promote neurite sprouting [41, 57, 140, 164]. 
Utilizing biomaterials to deliver such therapies may enable spatio-temporal control over 
their presentation, which is important for guiding nerve growth. Moreover, biomaterial delivery 
matrices protect and stabilize their cargo, which typically have short half lives in the body when 
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injected alone [165, 166]. Biomaterials achieve local, sustained delivery of therapeutic agents 
through one of three methods: physical entrapment, non-covalent interactions, or covalent 
incorporation. In effect, a biomaterial increases the bioavailability of a therapeutic factor by 
localizing it to the desired site of delivery and preventing its degradation once inside the body. 
The ability to deliver multiple drugs or growth factors in a controlled manner is also desired, to 
target the multitude of neural and inflammatory cells involved in nerve injury and regeneration. 
As such, delivery using biomaterials may modulate the environment of the injury site, provide 
neuroprotection and induce axon growth. In this section we will discuss biomaterials-mediated 
delivery of neurotrophins, proteins and drugs. 
1.2.3.1 Neurotrophins 
It has been shown that a 7 day continuous infusion of neurotrophins reduces axonal 
degeneration to a greater extent than a single, bolus injection [167]. Since most growth factors 
have a short half-life in vivo they need to be administered continuously; however continuous 
infusions are invasive, and cumbersome from a clinical standpoint. Biodegradable materials offer 
a viable solution to this challenge, for they can protect neurotrophins as well as present them to 
cells in a favorable manner. Such systems can be implanted in the CNS to release neurotrophins 
over time via diffusion and material degradation. In order to be effective, neurotrophin delivery 
systems must be non-toxic and provide a desired delivery profile. Properly-designed delivery 
systems hold immense promise for improving nerve regeneration. 
When neurotrophins are physically embedded within a biomaterial, their release is 
controlled by the porosity, structure, geometry and degradation rate of the material, and the 
diffusive properties of the growth factor. A preliminary study using PLA-block-PEG-block-PLA 
copolymer hydrogels delivered NT-3 in vivo for more than two weeks, enhancing behavioral 
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recovery when compared to the hydrogel alone [168]. Similarly, a PLA tubular scaffold 
containing BDNF was used to treat acute SCI, enhancing neuronal survival and rapid axonal 
growth into the implant compared to PLA alone [169]. However a lack of axonal penetration into 
the distal cord and no behavioral improvement over controls indicate BDNF alone is insufficient 
to achieve complete neural repair. These studies suggest that combination therapies are 
necessary, and delivery systems that rely upon physical entrapment offer the advantage of being 
able to incorporate multiple growth factors or bioactive cues.  
Neurotrophins can be incorporated into polymeric carriers such as micro- or 
nanoparticles to further sustain their release. Chitosan-NT-3 carriers were found to maintain the 
viability of rat NSCs as well as reduce the dosage of NT-3 required for the survival and 
differentiation of the cells [67]. When this system was implanted in a rodent model of traumatic 
brain injury, extensive neuronal fibers were found in the lesion epicenter and glial scarring was 
reduced compared to untreated controls and treatment with empty chitosan carriers [68]. 
However, no functional recovery was observed. Another group demonstrated that PLGA 
nanoparticles delivering GDNF preserved neuronal fibers at the injury site which resulted in 
significantly better behavioral recovery than empty PLGA microspheres [62]. However, glial 
activation was not reduced, further suggesting the potential benefit a combination of growth 
factors would provide. 
Non-covalent association is typically achieved by exploiting the electrostatic properties 
of neurotrophins; negatively-charged polymers such as heparin bind positive molecules and 
entrap them, thus slowing their release. Sakiyama-Elbert and colleagues modified fibrin gels in 
order to create a heparin-based delivery system for controlled growth factor release [137]. They 
synthesized a bifunctional peptide containing a fibrin-binding substrate at its N-terminal and a 
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heparin-binding sequence at its C-terminal. The peptide in turn binds heparin, which then 
associates electrostatically with growth factors in the matrix. This system has been used to 
successfully deliver GDNF, NGF, NT-3 and PDGF to both the CNS and PNS without 
compromising the bioactivity of the growth factors [64-66, 69-71, 170, 171]. Controlled delivery 
of NT-3 to spinal cord lesions was particularly effective in the short term, resulting in increased 
neuronal fiber sprouting and cell migration into the lesion at 2 weeks compared to unmodified 
fibrin gels (Figure 4) [70]. However at 12 weeks there was no significant difference in 
functional recovery between the experimental groups and saline controls [71]. By improving this 
drug delivery system such that it has a longer in vivo lifespan, the time period over which 
neurotrophins are delivered can be extended, and may promote sustained functional recovery. 
Since many different growth factors bind to heparin, this system also allows delivery of 
combinations of growth factors, although this has not yet been extensively studied.  
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 Figure 4. A heparin-based delivery system generated from modified fibrin gels (A) used to deliver NT-3 
causes infiltration of neurons (red) and astrocytes (green) into spinal cord lesions (B, 2) NT-3 delivery caused 
more neuronal growth than TBS-injected controls (B,1). I: intact cord; L: lesion.   
 
These investigations show the utility of growth factor delivery to enhance the 
regenerative capacity of natural and synthetic biomaterials. Many challenges remain to be 
overcome, such as increasing the loading efficiency, improving stability and maintaining 
bioactivity. As new information emerges about specific combinations of growth factors and 
optimal delivery conditions, materials scientists can design delivery systems specifically tailored 
towards the CNS environment.   
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1.2.3.2 Other Therapeutic Agents 
In addition to neurotrophic factors, biomaterials can be used to deliver other therapeutic 
agents, such as antibodies, anti-inflammatory drugs and other biomolecules that provide 
neuroprotection and inhibit secondary injury progression. Such systems are especially attractive 
for the delivery of larger molecules to the CNS, because the blood brain barrier inhibits their 
diffusion from the circulation into nervous tissue. For example the Nogo-66 receptor antagonist 
is capable of promoting neurite extension by blocking the inhibitory effects of Nogo, a myelin-
derived protein [172]. Covalent immobilization of Nogo-66 receptor antibodies to HA gels 
enhanced neuronal migration and growth in vivo [173, 174]. It even demonstrated the capacity to 
promote recovery of limb function in a rodent stroke model. Most recently a combination of 
Nogo antibody and poly-L-lysine in an HA hydrogel enhanced the viability and attachment of 
primary hippocampal neurons over either modification alone [52]. This latter study once again 
demonstrates the promise of combination therapies where the best results may be obtained by not 
one but many factors. 
ChABC is another important factor influencing nerve regeneration. It is a bacterial 
enzyme which digests inhibitory CSPGs, which are upregulated following CNS injury. ChABC 
promotes sprouting and functional recovery after injury to the CNS, but is limited by its 
instability at body temperature [164]. To overcome this problem and design a system capable of 
delivering bioactive chABC for extended periods, Lee and colleagues [85] developed a 
thermostabilized variation of chABC using the sugar trehalose. By encapsulating 
chABC/trehalose molecules in hollow lipid microtubes and embedding them in agarose gels, the 
the bioactivity of chABC was preserved for up to 2 weeks in vitro. Additionally, this system 
effectively digested CSPGs in vivo, as evidenced by immunostaining for CS-56. Using a 
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biodegradable hydrogel to deliver thermostabilized chABC would further increase its utility for 
clinical translation. 
A number of other therapeutic molecules have been delivered via the HAMC gel system 
developed by Shoichet’s group. HA gives the gel mechanical strength, while methylcellullose 
enables injectability. Erythropoietin, nimodipine, NBQX (a sodium channel blocker), human IgG 
(Immunoglobulin G) and several growth factors have all been delivered from HAMC over 
periods ranging from days to weeks, depending on the drug [57, 61, 140, 175]. This system is 
also capable of delivering molecules such as nimodipine, which possess limited solubility in 
aqueous environments. In order to vary the release time, drugs were incorporated into PLGA 
microparticles, which were then embedded in the HAMC gels. This stabilized the system and 
prolonged release to more than one month in vitro [57]. The HAMC system is a good example of 
one that is capable of delivering several different types of therapies, and would be particularly 
suited to study the efficacy of combination treatments. However in vivo delivery and degradation 
needs to be more thoroughly examined, as it should be capable of delivering therapeutics for 
several weeks. 
Similarly, PLGA nanoparticles have been used to deliver a plethora of biomolecules at 
varying rates, including methylprednisolone [98, 99, 152, 176, 177]. PLGA micro- and nano-
particle drug delivery systems are attractive due to their injectability, biocompatibility, and 
capacity for customized drug release. Additionally, they can be used alone or in combination 
with other materials, such as nerve conduits [176] or films [152]. The major advantages of 
degradable biomaterials-based delivery systems are that they (1) only require a single surgery for 
implantation, (2) can be designed to deliver drugs at a specific dose over a specific period of 
time, (3) localize delivery to a specific region of interest, and (4) protect their contents from 
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degradation, thus reducing the required dosage. As such, properly-designed drug delivery 
systems have huge implications for CNS repair.  
Though much progress has been made in developing biomaterials for nerve regeneration, 
significant functional recovery in vivo has been rare. Substantial challenges remain, such as 
finding the optimal combination of material and bioactive cues that both promote neurite 
outgrowth and inhibit growth inhibition. Additionally, a better understanding of developmental 
biology and wound healing will greatly help regenerative efforts. Insights in neurogenesis and 
the molecular changes after trauma will inspire the design of new biomimetic materials and 
treatment strategies.  Regeneration of the CNS is complex and challenging; the extent to which 
we are capable of reversing loss of function due to injury or disease remains unknown. What is 
certain is that nerve regeneration is an exciting area of research which faces great challenges and 
offers substantial opportunities for materials scientists to improve the lives of patients suffering 
nerve injuries.  
1.3 OBJECTIVES 
The objective of this work was to study the formulation and application of polymer-based 
delivery systems for use in the eye and CNS.   
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1.3.1 Objective 1: Deliver bevacizumab intravitreally using a biocompatible reverse 
thermal gel 
As previously discussed, the efficacy of intraocular drug delivery is limited by the short half-life 
of drugs, uptake by the systemic circulation, and diffusive barriers within the eye tissues. To this 
end, we sought to investigate novel drug delivery formulations which can improve ocular drug 
delivery. A functionalizable, biodegradable temperature sensitive gel, poly(ethylene glycol)-
poly(serinol hexamethylene urethane)(ESHU) is a solution at room temperature and undergoes 
phase transition to form a physical gel at body temperature. These features render ESHU 
injectable, and enable it to be combined with a multitude of molecules and proteins for 
therapeutic sustained drug delivery. Additionally, the potential for hydrogen bond formation 
between the ESHU backbone and therapeutic molecules may sustain release further. In order to 
test the hypothesis that ESHU can sustain the release of intravitreal drugs, we chose to focus on 
bevacizumab (Avastin®), a VEGF antibody that inhibits angiogenesis and is widely used by 
ophthalmologists to treat choroidal neovascularization. We first sought to successfully formulate 
the ESHU-bevacizumab delivery system, and determined its ability to release bevacizumab in 
vitro. Additionally, the cytocompatibility with ocular cells was studied. Next, the delivery system 
was injected into rabbit eyes to assess the effect of the gel’s presence on inflammation, 
intraocular pressure and retinal integrity. Finally, the ability of ESHU to sustain bevacizumab 
release in vivo was examined.  
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1.3.2 Objective 2: Improve the survival of transplanted bone marrow stromal cells in a 
rat model of spinal cord injury.  
Transplanted cells survive poorly in the injured spinal cord. The presence of inflammatory 
cytokines, reactive oxygen species, and inflammatory cells in the injury environment inhibit the 
growth and integration of transplanted cells which ultimately results in their death. 
Consequently, the reparative potential of these cells is eliminated within a few days. We 
hypothesized that transplanting the cells in ESHU gels would increase their survival, and 
therefore improve outcomes in injured rats. We tested our hypothesis in vitro by culturing 
BMSCs under conditions of oxidative stress, and in vivo by utilizing a contusion model of rat 
SCI.  
1.3.3 Objective 3: Study the effect of controlled growth factor release to the injured spinal 
cord using a coacervate-based protein delivery system.  
While improved cell transplant survival does improve outcomes in rats following SCI, we 
recognize the need for a combinatorial approach to further promote transplant survival and 
improve outcomes. With this in mind, we hypothesized that growth factor delivery to the injured 
spinal cord can be more efficacious when delivered via an injectable coacervate. Ultimately, the 
goal will be to combine growth factor and cell delivery. However, we must first test the growth 
factor delivery system in vivo. This system is composed of poly(ethylene argininylaspartate 
diglyceride) (PEAD), a polycation which binds heparin through electrostatic interactions. The 
PEAD-heparin system in turn is capable of binding a multitude of growth factors, making it 
attractive for treatment of SCI. We began by investigating sonic hedgehog (Shh), which is a 
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powerful morphogen involved in many processes in the developing CNS. Shh is not highly 
expressed in the adult mammalian CNS but is present throughout adulthood in zebrafish, whose 
nervous systems regenerate after injury. This suggests a potential role of Shh in the ability of the 
spinal cord to repair itself. We employed the same rat contusion model of SCI and injected the 
coacervate-Shh system directly into the injury region. We performed exhaustive behavioral and 
histological analysis in order to assess the effect of controlled Shh release on clinical outcomes.  
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2.0  FORMULATION AND CHARACTERIZATION OF REVERSE THERMAL GEL 
FOR OCULAR DRUG DELIVERY 
(Note: This chapter was published previously as: Park D, Shah V, Rauck BM, Friberg TR, Wang 
Y. An anti-angiogenic reverse thermal gel as a drug-delivery system for age-related wet macular 
degeneration. Macromolecular bioscience. 2013;13:464-9 and is reproduced here with 
permission from the publisher)  
2.1 INTRODUCTION 
 
Age-related macular degeneration (AMD) is the leading cause of irreversible vision loss in 
Americans over the age of 50. The wet—or exudative—form is characterized by abnormal blood 
vessel growth from the choroid, beneath the sensory retina. These vessels are associated with 
fluid leakage, which over time results in bleeding, retinal detachment, scarring and ultimately, 
loss of central vision [178-180].  
Intravitreal injection of anti-angiogenic drugs is currently the most widely utilized 
strategy for preventing choroidal neovascularization, and can decelerate vision loss significantly 
[181, 182]. More specifically, vascular endothelial growth factor (VEGF) is a major target of 
such treatments as its expression is elevated in patients with AMD, and is known to promote 
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blood vessel growth, enhance vascular permeability and stimulate inflammatory leukocyte 
recruitment [183-186]. While effective, the short half-life of VEGF-inhibiting drugs necessitates 
frequent painful injections, placing an overwhelming burden on patients and their families [187]. 
Moreover, such frequent injections increase the risk of retinal detachment, endophthalmitis, 
intraocular hemorrhage and other ocular complications [8, 9]. Therefore, a controlled release 
delivery system that reduces injection frequency while maintaining the drug’s efficacy would be 
highly beneficial to those suffering from AMD.  
With this goal in mind, we investigated the feasibility of a reverse thermal gel as an 
intraocular drug delivery vehicle for AMD. Reverse thermal gels are water-soluble and undergo 
spontaneous phase transition upon temperature elevation; ideally such a material would be in the 
solution phase at room temperature and form a physical gel when placed at body temperature 
[188-192]. When designed in this manner the gel can be loaded with bioactive macromolecules 
such as proteins, independent of their solubility properties. Since the gel forms rapidly in-situ, 
this system can achieve sustained, localized drug release. Previously we reported synthesis of an 
ABA type block copolymer, ESHU, as a reverse thermal gel in which A is hydrophilic and B is 
hydrophobic [193]. In this work, we used ESHU to successfully design an anti-angiogenic 
reverse thermal gel system by combining ESHU with bevacizumab. Bevacizumab was chosen as 
a model anti-angiogenic agent because it is the most commonly-used VEGF inhibitor for 
treatment of AMD, and is also administered intravitreally for other VEGF-mediated diseases 
such as central retinal vein occlusion and proliferative diabetic retinopathy [194-197]. We 
assessed the cytocompatibility of ESHU with bovine and human ocular cells, and studied the 
release kinetics of the bevacizumab-loaded gel in order to gauge the applicability of ESHU as an 
intraocular drug delivery vehicle.  
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2.2 MATERIALS AND METHODS 
2.2.1 Materials 
N-BOC-serinol, hexamethylene diisocyanate (HDI), tetramethyl benzidine, hyarulonic acid from 
Steptococcus equi (Mw: 1.5 million), and bovine serum albumin (BSA) were purchased from 
Sigma-Aldrich (St. Louis, MO, USA). PEG was obtained from Alfa Aesar (Ward Hill, MA, 
USA). Anhydrous diethyl ether was obtained from Fisher Scientific (Pittsburgh, PA, USA). 
Anhydrous chloroform and anhydrous N,N-dimethylformamide (DMF) were purchased from 
EMD (Gibbstown, NJ, USA). The Spectra/Por dialysis membrane (MWCO: 3,500-5,000) was 
bought from Spectrum Laboratories (Rancho Domingues, CA, USA). Recombinant human 
VEGF 165 was obtained from R&D System (Minneapolis, MN, USA). Horseradish peroxidase-
goat anti-human IgG (H+L) was purchased from Invitrogen (Carlsbad, CA, USA). Bevacizumab 
was purchased from Drugstore (Swedesboro, NJ, USA). 
2.2.2 Equipment 
Proton NMR spectra were recorded on a Bruker Avance 600 NMR. The molecular weight was 
calculated by gel permeation chromatography (GPC) on a Viscotek GPCmax VE2001 system 
using a Viscotek I-MBMMW-3078 column and a Viscotek 270 dual detector with THF as the 
eluent. Polyethylene glycol (American Polymer Standard) was used for calibration. Thermal 
behavior was studied by a thermostatted oscillating rheometer (AR2000, TA Instruments) 
equipped with 45 mm aluminum parallel plate geometry. 700 µl of the polymer solution was 
used for the measurements. Data was collected at an angular frequency of 1 rad/s with 0.5% 
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strain. Cell images were obtained on a Nikon TI Fluorescence Microscope. Fluorescence 
intensity in the images was recorded and analyzed using MetaMorph 7.7.4 software (Molecular 
Devices Sunnyvale, CA). 
2.2.3 Synthesis of ESHU 
ESHU was synthesized as described previously with minor modifications [193]. Briefly, the 
hydrophobic polyurethane block was synthesized by the reaction of N-BOC-serinol (0.5 g, 2.62 
mmol) with HDI (0.44g, 2.62 mmol) at 90 °C under nitrogen atmosphere. After reacting for 3 h, 
it was dissolved in 10 ml anhydrous DMF with excess HDI (0.88 g, 5.24 mmol) and stirred for 
24 h at 85 oC. After cooling to ambient temperature, the mixture was poured into excess 
anhydrous diethyl ether to precipitate the polymer. The precipitate was then dissolved in 2 ml 
anhydrous DMF and the purification process was carried out twice with diethyl ether. Then the 
precipitates were washed in 100 ml of anhydrous diethyl ether overnight to remove unreacted 
HDI. A transparent polyurethane middle block was obtained after drying at 45 °C under vacuum 
(yield: 98%). To conjugate the hydrophilic block, polyurethane (1 g) and PEG (4g, Mw: 550) 
were dissolved in 10 ml anhydrous DMF, and stirred for 24 h at 85 oC. After cooling to ambient 
temperature, the mixture was poured into excess anhydrous diethyl ether to precipitate out the 
polymer. The polymer was purified by dialysis in water at room temperature for 3 days. Finally, 
the dialyzed solution was freeze-dried and a transparent solid, ESHU, was obtained (yield: 95%, 
Mw: 7,244, Mw/Mn: 1.54). 1H FTNMR (CDCl3, δ in ppm): 4.83-5.23 [2H, -NH(CH2)6NH-]; 4.0-
4.2 [4H, -CH2(NH-BOC)CH2-]; 3.66 (4H, -OCH2CH2O-); 3.19 [4H, -NHCH2(CH2)4CH2NH-]; 
1.41 [9H, -OC(CH3)3]; 1.26 and 1.44 [8H, -NHCH2(CH2)4CH2NH-]. 
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2.2.4 Cell Culture 
To isolate bovine corneal endothelial (CE) cells, fresh whole cow corneas were excised with a 
scleral rim and then placed endothelium side up in plastic tube caps. The CE cells were 
enzymatically detached by application of 0.05% trypsin/0.5 mM EDTA with incubation at 37°C 
and harvested by gentle scraping. The CE cells were separated from Descemet’s membrane and 
cell suspensions were broken up by gentle pipetting and sieved through a 70-µm nylon mesh. 
The suspended CE cells were centrifuged, and pelleted cells to be used for the assay were 
directly re-suspended in 1% low-melting-point (LMP) agarose and used as described below. For 
culture, CE cells were re-suspended in DMEM (Invitrogen, Carlsbad, CA) supplemented with 
10% fetal bovine serum (Hyclone, Logan, UT), gentamicin, penicillin/streptomycin, and 
amphotericin B and cultured in 25 cm2 cell culture flasks at 37°C in 5% CO2 until 90% 
confluent.  
To test human retinal pigment epithelium (RPE), ARPE-19 (American Type Culture 
Collection) cells were suspended in 1% low-melting-point (LMP) agarose and centrifuged. The 
pelleted cells were directly re-suspended in 1% low-melting-point (LMP) agarose, then 
Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum, 
gentamicin, penicillin/streptomycin, and amphotericin B and cultured in 25 cm2 cell culture 
flasks at 37°C in 5% CO2 until 90% confluent.  
To test in vitro cytotoxicity, both primary bovine CE and ARPE-19 cells were incubated 
with 20 wt% ESHU in Glycated Human Serum Albumin (GHSA) medium for 24 and 72h, 
respectively at 37 oC in 5% CO2. Cells cultured on tissue culture polystyrene (TCPS) with no 
exposure to ESHU gel were used as a positive control. 
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2.2.5 Live-Dead Cytocompatibility Experiment 
After incubation with ESHU, cell viability was assessed using the Live/Dead assay. Cells were 
washed with DMEM containing 50 µg/ml Calcein AM for 20 min at 37 °C. In the final 5 min of 
incubation, 5 µg/ml propidium iodide (PI) was added, and then cells were washed with DMEM. 
Finally, nuclei were counterstained with 1µg/ml Hoechst 33342 for 5 minutes. The live and dead 
cells were analyzed by a fluorescence microscope. Comparative quantification of live cells was 
assessed using by a cell counting application sensitive to luminescence of Calcein AM, PI, and 
Hoechst staining in representative photomicrographs.  
2.2.6 Immunoassay of Bevacizumab 
The concentration of bevacizumab was measured by an enzyme linked immunosorbent assay 
(ELISA) as previously described with slight modification [198]. Ninety-six-well plates were 
coated with 1 µg/ml recombinant human VEGF 165 (100 µl/well) and incubated overnight at 
4°C. After washing three times with phosphate-buffered saline (PBS) containing 0.05% Tween-
20, wells were blocked with 1% bovine serum albumin in PBS for one hour at room temperature 
(200 µl/well). Wells were then washed five times with PBS containing 0.05% Tween-20 and 
stored at 4°C until use. Samples diluted in PBS containing 0.1% BSA were added to the plates 
and incubated for 3 h at room temperature. After washing three times with PBS containing 
0.05% Tween-20, 1 µg/ml horseradish peroxidase-goat anti-human IgG (H+L) was added (100 
µl/well) and incubated for 3 h at room temperature. After washing five times with PBS 
containing 0.05% Tween-20, color development was performed with 100 µl of tetramethyl 
benzidine, and the reaction was stopped by the addition of 100 µl of 1 M hydrogen chloride. 
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Optical density was measured on a Microplate Reader using Gen5 software (SYNERGY Mx, 
BioTek) at 450 nm with correction at 570 nm. A standard curve was prepared with bevacizumab 
concentrations ranging from 0.2 ng/ml to 3.125 µg/ml, and the linear region was used for the 
calculation. We measured the bevacizumab concentration in each sample thrice. 
2.2.7 Release Profile of Bevacizumab 
In vitro bevacizumab release studies were carried out in 1% (wt/v) of hyaluronic acid (HA) in 
PBS (pH 7.4) on a thermal rocker to mimic vitreous fluid composition [199] and eye motion, 
respectively. Gel solutions (200 µl) of 15 and 20% (wt/v) containing 0.5, 1, 3, and 5 mg of 
bevacizumab were injected into the HA solution through a 27-gauge needle at 37 oC within 5 
seconds. The needle was submerged into the solution completely to mimic clinical injection into 
the vitreous. The concentrations, 15 and 20%, were chosen in the range that the solution could be 
easily injected through the 27-gauge needle with a quick sol-gel transition time. At 
predetermined time points, three samples (20 µl each) were withdrawn from different positions, 
and the same amounts of fresh HA solution were added. The samples were diluted with PBS 
containing 0.1% (wt/v) BSA, and released bevacizumab was quantified using ELISA. The 
cumulative release was calculated based on the theoretical loading amount. 
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2.3 RESULTS AND DISCUSSION 
2.3.1 Cytocompatibility of ESHU with Ocular Cell Types 
In a previous study, we demonstrated that ESHU showed good biocompatibility in vitro with 
smooth muscle cells as well as in vivo when injected subcutaneously [193]. Here we investigated 
the suitability of ESHU for intraocular drug delivery. We first tested whether ESHU was 
compatible with intraocular cell lines. We chose two different lines—bovine corneal endothelial 
cells and human ARPE-19 cells—because these cell types are likely to be exposed to ESHU and 
its degradation products upon intravitreal injection. First we exposed primary bovine corneal 
endothelial cells to either control conditions (serum-free DMEM), or ESHU (15% w/v in 
DMEM). Cells were stained with Calcein AM/PI /Hoechst and viability was evaluated at 1, 12, 
and 24h. Representative photomicrographs were taken to quantify cell survival at each time point 
(Figure 5), and cell morphology was also assessed. Cells exposed to ESHU exhibited typical 
polygonal morphology that showed no difference from control conditions, suggesting that ESHU 
did not affect the growth of CE cells. Cell viability was expressed in terms of percentage cell 
death (PI nuclei/overall nuclei). There was no significant difference in the survival of CE cells 
between the control and ESHU groups (P>0.05, two- way ANOVA) at any time point (Figure 
6).  
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 Figure 5. Representative fluorescence micrograph images of bovine CE cells exposed to control (A,B) 
and ESHU (C,D) at 24h. Both groups show comparable intense nuclei staining (A,C) with scarce red-stained 
dead cells (B,D) indicating little cell death.  
 
Figure 6. In vitro cytotoxicity of ESHU against bovine CE cells after 1, 12, and 24 hour incubation. 
The number of dead CE cells was determined by counting the number of PI+ cells, and was expressed as a 
function of the total number of cells labeled by Hoechst staining. Values are expressed as the means ±SD 
(n=3).  
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ESHU showed good cytocompatibility with bovine CE cells, which are likely to be 
exposed to ESHU degradation products but not necessarily ESHU itself. Therefore, we needed to 
assess its compatibility with cells from the posterior segment of the human eye, as these cell 
types will be more directly exposed to the hydrogel. We used human ARPE-19 cells and exposed 
them to either DMEM (positive control) or ESHU, as described above. We found no significant 
cell death as indicated by the small number of PI-dyed dead cells (Figure 7). At each time point, 
total cell death was less than 1%, and statistically there were no differences between control and 
ESHU groups (P>0.05, two-way ANOVA) (Figure 8). Taken together, ESHU shows little to no 
cytotoxicity when cultured with both bovine and human ARPE-19 cells.  
 
Figure 7. Representative fluorescence micrograph images of human ARPE-19 cells exposed to 
control (A,B) and ESHU (C,D) at 72h. There was no difference between experimental groups in the total 
number of viable cells (A,C) and dead cells (B,D). 
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 Figure 8. In vitro cytotoxicity of ESHU against human ARPE-19 cells after 24, 48, and 72 hour 
incubation. The percentage of dead ARPE-19 cells was determined by expressing the number PI+ cells over 
the total number of cells labeled by Hoechst staining. Values are the means ±SD (n=3). 
2.3.2 Thermal Behavior of Bevacizumab-Loaded ESHU 
In order to examine whether bevacizumab-loaded ESHU underwent a phase transition at body 
temperature, we formulated a 20 wt% ESHU solution containing 1.25 mg of bevacizumab and 
monitored elastic modulus (G') changes during heating. We used 1.25 mg because it is the 
standard dose ophthalmologists inject intravitreally to treat AMD [200, 201]. The bevacizumab-
loaded ESHU solution underwent phase transition comparable to that of pure ESHU (Figure 9) 
[193]. The elastic modulus, G', which is indicative of a material’s stiffness and thus its phase, 
began to increase slightly from 32 oC to 33 oC, corresponding to the initiation of gelation. It then 
increased dramatically as temperature continued to rise and reached a maximum stiffness at 39 
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oC, indicating formation of a complete physical gel. Although G' steadily increased until 39 oC, it 
had reached about 90% of its maximum value at 37 oC, at which point the solution had already 
visibly formed a gel. Given the phase transition behaviors, bevacizumab-loaded ESHU 
maintained thermal gelling properties as expected.   
 
Figure 9. Thermal behavior of bevacizumab-loaded ESHU formulated with 20 wt% ESHU and 1.25 
mg bevacizumab. The steep increase in G' from 33 to 39 oC indicated a sol-gel phase transition. The phase 
transition behavior is similar to pure ESHU [193]. 
2.3.3 In Vitro Bevacizumab Release 
The key challenge of bevacizumab therapy for AMD is to prolong its release because the half-
life of free bevacizumab in human eyes after intravitreal injection is on the order of 7 to 10 days 
[202]. The intraocular concentration depends on local conditions, such as the presence of blood 
or fluid under the retina, the state of the vitreous gel and other factors. To evaluate the potential 
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of the ESHU-bevacizumab platform, we performed release tests in 7.5 ml of 1 wt% hyaluronic 
acid at 37 oC to mimic vitreous fluid, while gyroscopic shaking was conducted to simulate 
human eye motion. Four formulas, each of 15 and 20 wt% of ESHU containing 0.5, 1, 3, and 5 
mg of bevacizumab, gelled immediately upon injection into the 37 oC solution. The resulting 
sphere quickly sank to the bottom of the vessel, suggesting that the delivery system will sink out 
of the optical axis of the eye when injected in vivo. In all formulas, release was sustained without 
reaching plateau during the 17-week observation period (Figure 10). Release was more 
sustained with 20 wt% ESHU because ESHU formed a more rigid gel at the higher concentration 
[193], which presumably affects the diffusion path of bevacizumab. We also observed a small 
initial burst release for all the formulations. It is well-documented that burst release from 
injectable systems is higher than from pre-fabricated architectures such as implants [203]; thus 
we hypothesize that the observed burst release can be attributed to bevacizumab lost during the 
phase transition. Larger bursts were observed in the 15 wt% system, as well as with higher 
bevacizumab doses. This observation can be explained by the theory that at higher drug loading 
more is likely to be lost during the phase transition; additionally the lower ESHU concentration 
requires a longer gelation time, allowing for more bevacizumab to be released. This burst release 
might be helpful clinically, however, so as to provide immediate drug exposure in order to 
maximize efficiency. Moreover, the ability to control this burst by altering the ESHU 
concentration is attractive in that it can attenuate potential systemic effects of bevacizumab 
absorption, some of which can be serious, while still having an immediate therapeutic effect 
[204]. Thus, the bevacizumab-ESHU delivery system has three advantages over the current 
practice of direct bevacizumab injection in that the therapeutic window is much longer, release is 
sustained over 17 weeks in vitro, and injection frequency can be greatly reduced. 
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 Figure 10. The release profile of bevacizumab from (A) 15 and (B) 20 wt% ESHU systems. The 
release was sustained over the 17-week period with initial burst releases. The 20 wt% ESHU systems resulted 
in slower release rates, and smaller burst releases due to its higher concentration. 
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2.4 CONCLUSIONS 
We developed an anti-angiogenic reverse thermal gel system using ESHU and bevacizumab that 
demonstrates potential as a controlled release drug delivery system for AMD. ESHU appears to 
be an excellent material for ocular drug delivery, as it shows good cytocompatibility with bovine 
CE and human ARPE-19 cells, and an in vitro bevacizumab release profile extending to 17 
weeks. Moreover, ESHU is not limited to the use of bevacizumab; other water-soluble drugs can 
be easily loaded into the system as well, enabling multi-faceted treatment approaches. This 
preliminary work supports the concept that such a strategy may significantly reduce 
administration frequency, decrease treatment cost, and improve patient compliance.  
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3.0  INJECTABLE THERMORESPONSIVE HYDROGEL SUSTAINS THE 
RELEASE OF INTRAVITREAL BEVACIZUMAB IN VIVO 
(Note: This chapter was published previously as: Rauck BM, Friberg TR, Medina Mendez CA, 
Park D, Shah V, Bilonick RA, et al. Biocompatible reverse thermal gel sustains the release of 
intravitreal bevacizumab in vivo. Investigative ophthalmology & visual science. 2014;55:469-76 
and is reproduced here with permission from the publisher.) 
3.1 INTRODUCTION 
Choroidal neovascularization (CNV) is the hallmark of many blinding disorders, most notably 
wet age-related macular degeneration (AMD) and diabetic retinopathy. It is characterized by 
pathologic blood vessel growth which originates in the choroid and progresses through the 
Bruch’s membrane into the subretinal space [205]. These vessels are fragile and permeable, 
causing hemorrhage, retinal detachment, scarring and ultimately, loss of central vision. Elevated 
levels of vascular endothelial growth factor (VEGF) is a central cause of CNV [206-208], thus 
intravitreal injection of anti-VEGF medications such as bevacizumab (Avastin®) or ranibizumab 
(Lucentis®) has emerged as a leading treatment strategy [209-211]. The efficacy of these drugs, 
however, is severely limited by rapid clearance from the eye; their half-lives are on the order of 7 
days [198, 200]. This necessitates frequent injections, imposing a significant burden on patients 
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and increasing healthcare costs as well as procedure-related complications such as 
endophthalmitis, retinal detachment, cataract, and uveitis [212-215]. A delivery system that 
extends the presence of intravitreal drugs in the eye is therefore highly desirable for reducing 
injection frequency and adverse effects while maximizing therapeutic outcomes.   
A number of polymeric delivery systems have been considered by researchers for 
intravitreal drug delivery, including microparticles, which are well-tolerated in the eye and are 
capable of delivering drugs over a longer period of time [216, 217]. For example, microparticle-
encapsulated or PEGylated bevacizumab are more effective than bevacizumab alone in treating 
CNV in rats [217]. However, direct intravitreal injection of such microparticle formulations may 
result in rapid particle dispersion and cause turbidity of the vitreous humor, affecting vision. In 
situ-forming, injectable hydrogels are thus an attractive alternative for intravitreal delivery as 
they can be formulated to encapsulate drugs and sustain release locally. Studies with non-
degradable, thermally-responsive hydrogels have demonstrated excellent protein encapsulation, 
minimal toxicity, and easy injectability with no long-term effects on retinal function in vivo [31, 
32]. These studies established that thermoresponsive hydrogels are excellent candidates for 
intraocular drug delivery. 
Ideally, hydrogels for intravitreal administration should be biodegradable so as to avoid 
material accumulation in the vitreous with repeated injections over time. To this end, we 
investigated the utility of a biodegradable, thermally responsive hydrogel, poly(ethylene glycol)-
poly-(serinol hexamethylene urethane), or ESHU, to deliver bevacizumab in rabbit eyes. 
Previously, we have demonstrated that an aqueous solution of ESHU will undergo a sol-to-gel 
phase transition when the temperature is increased from room to body temperature, making it 
attractive for minimally invasive applications [193]. We hypothesized that ESHU would be a 
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suitable platform for intraocular drug delivery and demonstrated that it is compatible with cells 
from ocular sources, and capable of releasing bevacizumab over a 17 week period in vitro [218]. 
The aim of the present study was to demonstrate sustained bevacizumab release in vivo when 
compared to a standard, bolus injection. Additionally, we compared the cytocompatibility of 
ESHU to other commonly-used ocular biomaterials and assessed the in vivo biocompatibility of 
the gel.  
3.2 MATERIALS AND METHODS 
3.2.1 Materials 
N-Boc-serinol, hexamethylene diisocyanate (HDI), tetramethyl benzidine, and bovine serum 
albumin (BSA) were obtained from Sigma-Aldrich (St. Louis, MO, USA). Polyethylene glycol 
(PEG) was obtained from Alfa Aesar (Ward Hill, MA, USA). Anhydrous diethyl ether and 10% 
formalin were obtained from Fisher Scientific (Pittsburgh, PA, USA) and anhydrous N,N-
dimethylformamide was purchased from EMD (Gibbstown, NJ, USA). The Spectra/Por dialysis 
membrane (MWCO: 3500–5000) was purchased from Spectrum Laboratories (Rancho 
Domingues, CA, USA). The Live/Dead cytotoxicity assay kit was purchased from Molecular 
Probes (Carlsbad, CA, USA). Recombinant human VEGF165 was obtained from Peprotech 
(Rocky Hill, NJ, USA). Horseradish peroxidase-goat anti-human IgG was purchased from 
Invitrogen (Carlsbad, CA, USA). Bevacizumab was obtained from Genentech (South San 
Francisco, CA).  
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3.2.2 Preparation of Bevacizumab-Loaded ESHU 
ESHU was prepared as described previously [193, 218]. To prepare bevacizumab-loaded ESHU, 
the desired amount of polymer was measured out and sterilized via ethylene oxide (12 hour 
cycle, 20 °C, >35% relative humidity). The sterilized ESHU polymer was then dissolved in a 
solution of 25 mg/ml bevacizumab, or PBS for control gels, at 4 °C in the dark at a polymer 
concentration of 15% w/v.  
3.2.3 Injection Force Measurements  
The injection force of 15% w/v ESHU in bevacizumab was measured using a material testing 
system (Insight, MTS Systems, Eden Prairie, MN). Water and 1% hyaluronic acid were used as 
controls. Samples were loaded into syringes containing a 31G needle and the plunger was fixed 
to the instrument. The syringe was attached to a vial in order to collect the injected liquid, and 
compression tests were performed at speeds of 0.5, 1 and 3 mm/s. The force measurement at 
steady-state was considered to be the required injection force. Three separate runs were averaged 
for each sample at every speed.  
3.2.4 In Vitro Cytotoxicity 
Bovine corneal endothelial cells were isolated as previously described [218]. Cells were 
suspended in Dulbecco’s Modified Eagle Medium (DMEM, Invitrogen, Carlsbad, CA, USA) 
supplemented with 10% fetal bovine serum (Hyclone, Logan, UT, USA), 
penicillin/streptomycin, gentamicin, and amphotericin B, then incubated at 37 °C in 5% CO2 
 51 
until cells were 90% confluent. For in vitro cytotoxicity assays, cells were exposed to one of four 
experimental conditions: serum-free media (control), 15% w/v ESHU in DMEM, 
perfluorooctane (PFO), or 5000cs silicone oil. As commonly utilized ocular materials, PFO and 
silicone oil served as control groups, and all conditions were run in triplicate. At 1, 12 and 24 
hours, cell viability was assessed using the Live/Dead assay. Cells were stained with 50 µg/ml 
Calcein AM (in DMEM) at 37 °C for 20 min, and during the last 5 min of incubation, 5 µg/ml 
propidium iodide (PI) was added. After washing in DMEM, nuclei were stained with 1 µg/ml 
Hoechst 33342 for 5 min. Representative images were taken of each culture using a fluorescence 
microscope. Cell viability was expressed as the ratio of PI-positive cells to Hoechst-stained cells 
in each sample.  
3.2.5 Intravitreal Injection 
All animal experiments were conducted in compliance with protocols approved by the 
Institutional Animal Care and Use Committee at the University of Pittsburgh, with strict 
adherence to guidelines of the National Institutes of Health, United States Department of 
Agriculture, and the ARVO statement for the Use of Animals in Ophthalmic and Vision 
Research. Male New Zealand White rabbits (8 weeks old, Charles River Laboratories, Boston, 
MA) were used for this study. Prior to injection, animals were anesthetized by intramuscular 
administration of ketamine/xylazine (40 mg/kg). Topical antibiotic (Vigamox, Alcon 
Laboratories, Fort Worth TX, USA) and anesthetic (Proparacaine, Falcon Pharmaceuticals, Fort 
Worth TX, USA) eye drops were applied prior to injection. Intravitreal injections were 
conducted through the pars plana (2.5 mm posterior to the limbus). Eyes received one of three 50 
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µl injections: 1.25 mg bevacizumab in saline (n=3), 1.25 mg bevacizumab in 15% ESHU (n=4), 
or 15% ESHU in saline (n=2). Uninjected eyes served as healthy controls (n=2).  
3.2.6 Clinical Examination 
Clinical evaluations were conducted pre- injection, immediately after injection, 15 minutes post-
injection and at 1, 3, and 7 days, and weekly thereafter for ten weeks. Clinical examinations 
included analysis of inflammatory response via indirect ophthalmoscopy and IOP measurements.   
3.2.6.1 Indirect Ophthalmoscopic Observation 
To observe the gel in situ and identify potential gross inflammation in the anterior or 
posterior segments, eyes were dilated using tropicamide 0.5% (Bausch and Lomb, Tampa, FL) 
and phenylephrine 2.5% (Alcon, Fort Worth, TX) and examined using an indirect 
ophthalmoscope with a 20 diopter lens (Nikon, Tokyo, Japan). 
3.2.6.2 Intraocular Pressure 
IOP was monitored using a rebound tonometer (TONOVET, Icare, Helsinki, Finland). 
Baseline IOP measurements were obtained following anesthesia, prior to injection. 
Measurements were taken again immediately following injection, 15 minutes later, and at each 
sampling time point thereafter. Three measurements per eye were averaged.  
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3.2.7 In Vivo Bevacizumab Release  
Aqueous humor samples were obtained via anterior chamber paracentesis with a 30G syringe 
(approx. 100 µl sample volume) at 1, 4, and 7 days post injection, and weekly thereafter until 
sacrifice. The concentration of bevacizumab present in samples was determined using ELISA. 
Wells of 96-well plates were coated with 100 µl of 1 µg/ml recombinant human VEGF165 
overnight at 4 °C. Following 3x washing with PBS containing 0.05% Tween-20, wells were 
blocked for 1h at room temperature with 1% BSA in PBS. Samples were diluted with 0.1% BSA 
and added to the plates following 5x washing. After 1h at room temperature, wells were washed 
3 times and horseradish peroxidase-goat anti-human IgG (diluted 1:2000 in 0.1% BSA) was 
added to each well for 1h at room temperature. Wells were then washed five times and color 
development was performed using 100 µl of tetramethyl benzidine. The reaction was stopped by 
addition of 100 µl of 1M hydrogen chloride. A standard curve of bevacizumab (linear region: 
0.05 ng/ml to 1 ng/ml) was used to determine the concentration of bevacizumab in samples.  
3.2.8 Histological Analysis 
At 9 weeks, 4 of 5 animals were sacrificed and the eyes were explanted for histological analysis. 
One animal was sacrificed at 18 weeks to assess long-term compatibility. Eyes were fixed in 
10% formalin, embedded in paraffin and sectioned at 5 µm thickness. Following de-
paraffinization, sections were then stained with hematoxylin & eosin, Masson’s Trichrome, and 
Periodic Acid Schiff (PAS) stain to assess eye morphology.  
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3.2.9 Statistical Analysis 
Data are expressed as mean ± standard error of the mean (SEM). One-way analysis of variance 
(ANOVA) with Tukey post-hoc testing was used to determine statistical differences between 
groups for IOP and injection force data. Two-way ANOVA was used for the live/dead assay. 
Differences were considered significant at p<0.05. For in vivo studies, the observed 
bevacizumab concentrations in anterior chamber samples were modeled as a nonlinear function 
of time (day) and treatment group using a first order compartment model for power transformed 
bevacizumab concentrations. To appropriately account for the longitudinal repeated 
measurements, a nonlinear mixed effects model was used. The R language and environment for 
statistical computing and graphics (Version 2.15.1) [219] with the nlme (Version 3.1-108) R 
package [220] were used to compute the maximum likelihood estimates and confidence intervals 
via the nlme (nonlinear mixed effects model) and SSfol (self-starting first order compartment 
model) functions. A detailed description of the model and parameter estimates can be found in 
Appendix A.   
3.3 RESULTS 
3.3.1 Feasibility of ESHU Injection 
The small needle commonly used for intravitreal injection makes viscous materials difficult to 
inject; therefore the force required to push ESHU through a 31G needle was quantified using 
compression testing. Water and 1% hyaluronic acid (HA) were used as controls in order to relate 
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the injection force to common materials (Figure 11). Intuitively, the force required to inject 
ESHU (15% w/v dissolved in 25 mg/ml bevacizumab) increased in a speed-dependent manner. 
At all three speeds tested, the injection force for ESHU was larger than that of water, but less 
than 1% HA (p<0.05 in all conditions tested). A swift 3 mm/s required an easily manageable 
injection force of 6.291± 0.197 N, compared to 7.865 ± 0.083 N for HA. We next observed the 
phase transition behavior of ESHU following injection to a solution of HA heated to 37 °C, to 
mimic intravitreal administration. ESHU immediately undergoes the sol-gel phase transition and 
forms a spherical hydrogel (Figure 11C).  
 
Figure 11. The force required to inject a 15% w/v solution of ESHU (A) through a 31G needle is less 
than for a 1% solution of HA, a commonly-injected ophthalmic material (B). Upon injection to a solution of 
hyaluronic acid at 37°C, ESHU forms a spherical hydrogel (C). 
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3.3.2 In Vitro Cytotoxicity of ESHU 
Cytotoxicity testing was performed using primary bovine corneal endothelial cells. Cells were 
exposed to either serum-free media (control), ESHU (15% w/v in DMEM), silicone oil, or 
perfluorooctane (PFO). PFO is used intraoperatively during vitreoretinal surgery, and silicone oil 
is used commonly as a vitreous substitute for the repair of complex retinal detachments [221, 
222]. At 1, 12 and 24 hours, cells were stained with Calcein AM, PI and Hoechst and toxicity 
was quantified as the number of PI+ cells compared to the total number of Hoechst+ cells. In 
cultures treated with ESHU and PFO, no significant cell death occurred throughout the 24h 
culture period (Figure 12, p > 0.05). Silicone oil treated cultures underwent substantial cell death 
at each time point compared to both control and ESHU groups, with approximately 76% death at 
24h. Qualitatively, cells exposed to ESHU showed little to no evidence of cellular damage and 
appeared morphologically identical to control groups.  
 
Figure 12. Bovine CE cells survive well over a 24-hour period following exposure to ESHU gels, with 
no significant difference when compared to TCPS controls. In contrast, silicone oil caused significant cell 
death compared to all other experimental groups (p<0.05). 
 57 
3.3.3 Effect of ESHU on Intraocular Pressure  
IOP measurements were taken immediately before and after injection and prior to each sampling 
time point throughout the course of the study. Measurements show that IOP spiked sharply 
following injection of both ESHU and bevacizumab solutions, and returned to baseline levels 
within 15 minutes (Figure 13). Throughout the remainder of the study, IOP remained at baseline 
and was not significantly different from control eyes.  
 
Figure 13. IOP measurements return to baseline values 15 minutes following intravitreal injection. 
Throughout the study, IOP was not significantly different between ESHU and control groups (p>0.05).  
3.3.4 Effect of ESHU on Inflammatory Response  
In addition to IOP measurements, gels were observed and photographed in situ through indirect 
ophthalmoscopy. 24 hours post-injection, injected hydrogels had sunk to the bottom of the 
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vitreous space. Animals displayed no signs of discomfort or external signs of inflammation 
(redness or tearing). Throughout the study period, the gels remained translucent and ovoid in 
shape, with no evidence of inflammation or cellular accumulation on the gel surface (Figure 
14A). In the animal that was sacrificed at 18 weeks, gels appeared to become more transparent as 
degradation occurred. Additionally, the long-term presence of the gel did not seem to affect the 
eye based on indirect observation, or histologically. Though ESHU appears to fill a large portion 
of the vitreous from the indirect, it should be noted that the view includes only part of the 
vitreous space. The gels are typically 3-4 mm in diameter and occupy approximately 3% of the 
vitreous volume. Following sacrifice, eyes were processed for histological analysis and 
representative H&E images are shown in Figure 14B. The retinal layers are intact with no 
evidence of inflammation, corroborating the indirect observations. 
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 Figure 14. ESHU is biocompatible in the eye. (A) Indirect images of the hydrogel in the vitreous 
space. The surface of the gel (traced in black) is free of inflammatory cells and the vitreous humor is clear. 
(B) Hematoxylin and eosin stains comparing the retinal structure of ESHU and control groups. The two 
groups are morphologically indistinguishable, suggesting that the presence of ESHU did not adversely affect 
retinal health. Scale bar: 100 µm. 
3.3.5 In Vivo Bevacizumab Release 
We sought to compare the concentration of bevacizumab in rabbit eyes receiving the ESHU 
delivery system to a single bolus intravitreal injection. We injected 1.25 mg of bevacizumab (50 
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µl) in both experimental groups to allow for direct comparison to the clinically administered 
dose. Anterior chamber (AC) paracentesis was performed to obtain aqueous humor samples, and 
ELISA was used to quantify the amount of bevacizumab present (Figure 15). A first-order 
compartment model was used to model the bevacizumab concentration in experimental groups 
over time. The fixed effect parameters were found to be well-estimated by the model (Tables A1 
and A2 of Appendix A). The concentration in bevacizumab-only groups peaks earlier and is 
lower than for ESHU-bevacizumab. The parameters that characterize these differences are highly 
statistically significant (p<<0.05). On average, the ESHU maintained a bevacizumab 
concentration that was 4.7-fold higher than eyes which received a bolus injection. It should be 
noted that any bevacizumab present in control eyes was below the limit of detection for the 
ELISA assay and was therefore considered to be negligible. Thus this data is not shown in Figure 
15.  
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 Figure 15. ESHU sustains bevacizumab release for over 9 weeks. The concentration of bevacizumab 
in AC samples over time is plotted on a semi-log scale (A). On average, animals receiving the delivery system 
had 4.7-fold more bevacizumab present (B).  
3.4 DISCUSSION 
The present study demonstrated that ESHU, a thermally responsive hydrogel, is feasible for 
intravitreal injection, is biocompatible in vitro and in vivo, and can maintain bevacizumab 
concentrations at levels approximately five times higher than in controls. The force required to 
inject ESHU is less than that for HA, a highly viscous glycosaminoglycan and major component 
of the vitreous humor. HA is used extensively in ophthalmic surgery, and cataract surgery in 
particular as an injectable vitreous substitute [223, 224]. The injection force data indicate that 
ESHU formulations are suitable for intravitreal injection through small gauge needles without 
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requiring significant effort to administer. Upon injection into a solution of HA heated to 37 °C, 
ESHU formulations undergo a rapid sol-gel phase transition and form spherical-to-ovoidal 
shaped hydrogels. This transition occurs rapidly, yet not instantaneously, enabling time for 
injection without gelation occurring within the needle. ESHU does not cause significant cell 
death when cultured with bovine corneal endothelial cells; in previous work we demonstrated 
ESHU had good cytocompatibility with both bovine corneal endothelial and retinal pigment 
epithelial cells.[218]. The experiments in this study elaborated upon these results by comparing 
ESHU to other synthetic materials that are commonly used in retinal surgery – silicone oil and 
perfluorooctane. The substantial cell death caused by silicone oil treatment, which is commonly 
used clinically, suggests that ESHU will be well-tolerated in vivo. While ESHU appeared to 
cause less cell death than PFO at 12 and 24h, this difference was not statistically significant. 
Taken together, these results indicate that ESHU is less toxic than other, FDA-approved 
materials for ocular applications and should be biocompatible in the eye.  
Next, intravitreal injections of bevacizumab, ESHU dissolved in bevacizumab, or ESHU 
dissolved in PBS were performed in rabbits. IOP was measured throughout the study as one 
metric of ocular health. The initial spike following injection is typical and secondary to a small 
increase in volume of the eye, and is a function of the ocular rigidity [222]. As IOP variations 
can be indicative of pathologies such as trabeculitis and retinal detachment [225, 226] the normal 
measurements observed throughout the study suggest that the presence of ESHU did not cause 
significant damage to the eye. Indirect and histological observation revealed that the gel 
remained spherical-to-ovoidal in shape throughout the course of the study, sunk to the bottom of 
the eye within one day of injection, caused no significant inflammatory response to the presence 
of ESHU and did not affect retinal structures. In one animal that remained under observation for 
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18 weeks, the gel became more transparent over time, suggesting occurrence of degradation. 
Previously it was demonstrated that ESHU undergoes approximately 10% and 20% degradation 
after 45 days in vitro in PBS in the absence and presence of cholesterol esterase respectively 
[193]. It was hypothesized that in vivo degradation would occur more rapidly; however the 
immune privileged state of the eye may have protected ESHU from enzyme and cell mediated 
breakdown, resulting in minimal degradation. Current studies are focused on introducing more 
rapidly degrading bonds to the ESHU backbone in order to control its degradation rate. 
To our knowledge, this is the first study to date which compares the long-term in vivo 
release of bevacizumab from thermoresponsive biodegradable hydrogels to bolus intravitreal 
administration. The suitability of thermoresponsive hydrogels for intravitreal applications has 
previously been explored using non-degradable poly(N-isopropylacrylamide) (PNIPAAM)-based 
hydrogels, as well as biodegradable poly(2-ethyl-2-oxazoline)-b-poly(ε-caprolactone)-b-poly(2-
ethyl-2-oxazoline) (PEOz-PCL-PEOz), or ECE gels [31-34]. These studies demonstrated that 
intravitreal injection of synthetic hydrogels caused no long-term (up to 2 months) changes to 
retinal function, IOP or histomorphology in rabbits, corroborating our observations. However, 
PNIPAAM gels are non-degradable, and therefore would require surgical removal. Additionally, 
their synthesis protocol requires free radical polymerization and involves the use of potentially 
toxic initiators, whereas ESHU synthesis requires no catalysts. ESHU polymer is biodegradable, 
and would thus disappear with time. Compared to the biodegradable ECE gel, we previously 
demonstrated that ESHU releases bevacizumab for approximately 17 weeks in vitro, compared 
to less than 3 weeks in the ECE gel [218]. A potential reason for this is hydrogen bond formation 
between the ESHU gel backbone and bevacizumab, which would sustain the release of the drug. 
These prior studies have elegantly demonstrated the benefit that minimally invasive hydrogels 
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may provide; however did not demonstrate sustained release in an animal model. We built upon 
their work to show that intravitreal injection of a clinically-relevant volume of bevacizumab-
containing hydrogel sustains bevacizumab release in vivo and does not elicit a chronic 
inflammatory response. Though the eye displays immune privilege and is generally less 
susceptible to foreign body responses, [227] chronic inflammation can manifest itself as 
alterations in retinal morphology, which was not observed in this study. The nearly five-fold 
increase in bevacizumab concentration in ESHU-injected eyes suggests that the polymer 
functions to protect bevacizumab from degradation and should therefore be more effective in 
treating CNV. Future work will focus on optimizing the drug release kinetics by varying drug 
dose, polymer concentration, molecular weight and degradation, as well as confirming the 
efficacy of the drug delivery system in a non-human primate model of CNV. According to some 
researchers, such efficacy studies should be done in primates, as bevacizumab is humanized and 
its effect on CNV can be species-specific [228]. 
3.5 CONCLUSIONS 
We have studied the feasibility of a unique thermally-responsive hydrogel, ESHU, as an 
intraocular drug delivery vehicle. ESHU is easily injectable and from a clinical standpoint, its 
administration would be no different than the current practice of injecting bevacizumab. In vivo, 
ESHU gels are well tolerated with little to no evidence of inflammation, and are capable of 
sustaining bevacizumab release over 9 weeks. Because the polymer is an injectable solution, it 
can be used to sustain the release of many different medications and can be useful for other 
ocular diseases as well as diseases in other tissues.  
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4.0  INJECTABLE THERMORESPONSIVE HYDROGELS ENHANCE CELLULAR 
TRANSPLANT SURVIVAL AND IMPROVE OUTCOMES FOLLOWING 
TRAUMATIC SPINAL CORD INJURY 
(Note: This chapter was published previously as: Ritfeld GJ, Rauck BM, Novosat TL, Park D, 
Patel P, Roos RA, et al. The effect of a polyurethane-based reverse thermal gel on bone marrow 
stromal cell transplant survival and spinal cord repair. Biomaterials. 2014;35:1924-31 and is 
reproduced here with permission from the publisher) 
4.1 INTRODUCTION 
Cell therapy is promising for repair of the damaged nervous system [229-231]. Bone marrow 
stromal cells (BMSCs) are candidate cells for such therapies because of their repair proficiency 
and relative accessibility [232-235]. BMSCs support repair of a myriad of other ailments 
including cardiomyopathy, muscle dystrophy, and wound healing [236-238]. Intraneural BMSC 
transplants are thought to elicit repair through paracrine effects [239-242]. However, these 
effects are likely limited due to low transplant survival in damaged nervous tissue [243-246]. 
Cell transplants may be lost due to various events including inflammation [247] and 
oxidative stress [248-252], which are initiated rapidly after injury. Thus, measures to protect cell 
transplants against these death-mediating mechanisms may increase transplant survival and 
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potentially improve their reparative effects. One strategy to improve transplanted cell survival is 
by using the synthetic poly(ethylene glycol)–poly(serinol hexamethylene urethane) or ESHU, 
which is a reverse thermal gel with good biocompatibility and degradability [193, 218]. ESHU is 
a copolymer with two hydrophilic poly(ethylene glycol) blocks flanking a hydrophobic 
poly(serinol hexamethylene urethane) block [193]. The presence of polyurethane [253, 254] may 
provide ESHU with antioxidant capacity. ESHU dissolves in water and undergoes phase 
transition with increasing temperatures to form a physical gel at 37 °C, which makes it especially 
practical for treatment of closed injuries [255]. 
ESHU was shown to have good biocompatibility with nervous tissue in the ocular system 
[218, 256]. A beneficial feature of ESHU is that the repeating units of the polymer contain 
protected amine groups, providing an easy path to functionalization using biomolecules or other 
signaling molecules that can offer enhanced bioactivity of the gel in vivo. One example is to 
functionalize ESHU through these amine groups with the pentapeptide, IKVAV, which in pilot 
experiments was shown to produce a neural interface similar to laminin. 
We hypothesized that ESHU protects intraneural BMSC transplants from death leading to 
improved repair. This premise was tested in vivo using an adult rat model of spinal cord 
contusion [235, 243, 244] assessing BMSC transplant survival, inflammation, anatomical 
restoration, and functional recovery and in vitro using BMSC cultures determining the effects of 
ESHU on survival of BMSCs under oxidative stress. 
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4.2 MATERIALS AND METHODS 
4.2.1 Ethics and Surgical Approval  
Before and after surgery, rats were housed following guidelines of the National Institutes of 
Health and the United States Department of Agriculture. The rats were kept within a double-
barrier facility in standard rat cages with continuous supply of fresh air, water, and food. All 
procedures were approved by the Institutional Animal Care and Use Committee at the University 
of Pittsburgh. 
4.2.2 Transplant Preparation 
We harvested BMSCs from femurs of harvested BMSCs from femurs of female adult Sprague 
Dawley rats according to a previously described protocol (Figure 1a) [235, 243, 257]. Isolated 
cells were grown in Dulbecco's Modified Eagle Medium (DMEM, Sigma–Aldrich, Allentown, 
PA, USA) with 10% fetal bovine serum (Mediatech, Manassas, VA, USA) and 1% 
penicillin/streptomycin (Invitrogen, Grand Island, NY, USA). To enable detection after 
transplantation, first passage cells were transduced to express green fluorescent protein (GFP) 
using lentiviral vectors (Figure 16a) [235, 243, 244]. Fourth passage cells positive for the BMSC 
markers, CD90 and CD105 and negative for blood cell markers, CD34, CD45 and HLA-DR 
[244, 258, 259] were used for the experiments. 
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 Figure 16. Schematic representations of transplant preparation and ESHU. (a) Isolation and 
transduction of bone marrow stromal cells. Plastic-adherent cells from femurs of adult Sprague-Dawley rats 
were collected, lentivirally transduced with green fluorescent protein, and passaged four times before used 
for transplantation. (a’) Green fluorescent protein-expressing BMSCs in culture. Smaller panels show 
examples of cultured BMSC morphologies. (b) Structural formula of ESHU with the urethane bond in gray 
box. Bar = 50 µm in a’ and 25 µm in panels below.  
4.2.3 ESHU 
The preparation of ESHU (Figure 16b) was previously described [193]. In brief, polyurethane 
blocks were synthesized by melting N-BOC-serinol (Sigma–Aldrich) under nitrogen and slowly 
adding hexamethylene diisocyanate (HDI; TCI America, Wellesley Hills, MA, USA) to initiate 
polymerization via urethane bonds. Both ends of polyurethane were capped with an isocyanate 
group using additional HDI and then dissolved in anhydrous dimethylformamide. Diethyl ether 
(Fisher Scientific, Pittsburgh, PA, USA) was used to precipitate out the polymer and remove 
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unreacted hexamethylene diisocyanate. Polyethylene glycol (Alfa Aesar, Ward Hill, MA, USA) 
was coupled onto the polyurethane blocks under nitrogen, dissolved in dimethylformamide 
(EMD, Gibbstown, NJ, USA), and precipitated in and washed with diethyl ether. For 
purification, ESHU was dissolved in water and dialyzed (3500 MWCO) for 48 h and finally 
freeze-dried. In our experiments, a 16% w/v ESHU solution in phosphate-buffered saline (PBS; 
pH 7.4) was prepared and sterile-filtered before use. 
4.2.4 Surgical Procedures 
A model of adult rat spinal cord contusion [260, 261] was used to test our hypothesis. Female 
adult Sprague Dawley rats (200 g, n = 80; Charles Rivers Laboratory, Wilmington, MA, USA) 
were anaesthetized using intraperitoneal injection of ketamine (60 mg/ml; Butlerschein, Dublin, 
OH, USA) and dexdomitor (0.5 mg/kg; Pfizer, New York, NY, USA). The tenth thoracic spinal 
cord segment was contused using a force of 200 kDyne (Infinite Horizon IH-0400 impactor; 
Precision Systems and Instrumentation, LLC, Versailles, KY, USA) [235, 243, 244]. The wound 
site was rinsed with sterile PBS with 0.1% gentamicin (VWR, Radnor, PA), the muscles were 
sutured in layers, and the skin was closed with Michel wound clips (Fine Science Tools, Foster 
City, CA, USA). All rats included in the studies had an impact within 5% of the intended force, 
resulting in a 0.9–1.8 mm spinal cord compression and a Basso-Beattie–Bresnahan (BBB) [262, 
263] score ≤ 1 at day 1 and ≤5 at day 3 post-impact. Three days post-injury, rats were sedated 
and injected into the contusion with 5 μl ESHU or PBS with 5 × 105 BMSCs, or ESHU or PBS 
only. 
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4.2.5 Post-Surgery Procedures 
Antisedan (1.5 mg/kg; Pfizer) was injected subcutaneously to reverse the effects of dexdomitor. 
An intramuscular injection of gentamicin (6 mg/kg; VWR), a subcutaneous injection of Rimadyl 
(5 mg/kg; Pfizer), and a subcutaneous injection of Ringer's solution (10 ml on surgery day, 5 ml 
thereafter; Butlerschein) were administered daily for the first three days post-injury. After the 
intraspinal injection at three days post-injury, the rats received gentamicin for four days and 
Ringer's and Rimadyl for three days. Bladders were manually emptied twice daily until reflex 
voiding occurred [235, 243]. Rats were monitored daily throughout the experiments. Rats were 
fixed at 15 min, one, four, or six weeks after injection. All rats survived without requiring pain or 
distress treatment. 
4.2.6 Motor Function Assessment 
Overground walking ability was assessed using the BBB test [262, 263] weekly for six weeks 
post-injection (n = 10/group). Rats were tested for 4 min by two testers unaware of the 
treatments. Rats were familiarized with the open field and baseline values were determined 
before surgery. Scores were averaged per experimental group. Higher motor functions were 
assessed at six weeks post-injury using the BBB sub-score [264, 265] as previously described 
(n = 10/group). Scores were averaged per experimental group. Sensorimotor function of the 
hindlimbs was assessed before (baseline) and at six weeks post-injection using horizontal ladder 
walking (n = 10/group) [266, 267]. Slips of the foot and part of lower leg and slips of the full leg 
were counted and expressed as a percentage of the total number of steps. Scores were averaged 
per experimental group. 
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4.2.7 Histological Procedures 
Rats were anaesthetized and transcardially perfused with 300 ml PBS followed by 400 ml 4% 
paraformaldehyde (Sigma–Aldrich) in PBS. Spinal cords were dissected, post-fixed overnight in 
the same fixative, and transferred to 30% sucrose (Fisher Scientific) in PBS for 48 h. A 12 mm-
long spinal cord segment centered at the injury epicenter was cut in 20 μm-thick horizontal 
cryostat sections (CM 1950; Leica Biosystems, Buffalo Grove, IL, USA). Every twelfth section 
was stained with cresyl violet (0.5%; Sigma–Aldrich) for cytoarchitecture analysis and spared 
tissue volume assessment. Other section series were used for immunocytochemistry. Sections 
were analyzed using an Axio Observer Z1 fluorescent microscope (Zeiss, Thornwood, NY, 
USA) with StereoInvestigator® (MicroBrightField, Inc., Williston, VT, USA). 
4.2.8 Immunocytochemistry 
Tissue sections were incubated in 5% normal goat serum (Vector Labs, Burlingame, CA, USA) 
and 0.03% Triton X-100 (Sigma–Aldrich) in PBS for 1 h followed by the primary antibody for 
2 h at room temperature and then overnight at 4 °C. Rabbit polyclonal antibodies against glial-
fibrillary acidic protein (GFAP) were used to detect astrocytes (1:200; Dako North America, 
Inc., Carpinteria, CA). Mouse monoclonal antibodies against ED1 were used to detect 
macrophages (1:100; Millipore, Temecula, CA). BMSCs in vitro on 8-chamber culture slides 
(BD Falcon, Franklin Lakes, NJ; see also below) were fixed with 4% paraformaldehyde in PBS 
for 10 min and stained with monoclonal antibodies against caspase 3 (rabbit, clone D3E9) to 
detect apoptotic cells (1:100; Millipore) and 8-oxo-2′-deoxyguanosine (8-oxo-dG; mouse, clone 
483.15) to detect cells with DNA damage (1:200; Millipore). After washing twice in PBS for 
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20 min, sections or cells were incubated with goat-anti-rabbit and goat anti-mouse Alexa Fluor 
594 (1:200; Life Technologies, Grand Island, NY, USA) for 2 h at room temperature. DAPI 
(0.2 μl/ml; Sigma–Aldrich) was used to stain nuclei. Sections were covered with glass slips in 
fluorescent mounting medium (Dako North America, Inc.) and stored at 4 °C. Sections were 
analyzed using an Axio Observer Z1 fluorescent microscope (Zeiss, Thornwood, NY, USA) with 
StereoInvestigator® (MicroBrightField, Inc., Williston, VT, USA). 
4.2.9 Cell Quantification 
StereoInvestigator® (MicroBrightField, Inc.) was used to determine the numbers of GFP-positive 
BMSCs in the injury site [243, 268] at seven days post-transplantation (n = 6/group) in every 
twelfth section and the numbers of caspase 3- and 8-oxo-dG-positive BMSCs in cultures (see 
below). All assessments were done by personnel blinded to the treatment groups. For GFP-
positive BMSCs in the contusion, sections were 240 μm apart spanning the width of the spinal 
cord. In every section the area containing GFP-positive cells was outlined manually at 2.5× 
magnification and covered with a 250 × 250 μm grid. At 60× magnification with oil immersion, 
GFP-positive cells with a discernible DAPI-stained nucleus were marked using the optical 
fractionator with a 60 × 60 μm counting frame [235, 243, 268]. The numbers of immunostained 
cells in cultures were similarly determined. The numbers of GFP-positive cells were expressed as 
a percentage of the number of transplanted cells (±SEM). The numbers of caspase 3- and 8-oxo-
dG-positive cells were expressed as a percentage of the number of seeded cells (±SEM). The 
numbers were averaged per experimental group. 
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Image J Software was used to determine the number of ED1-immunoreactive 
macrophages in the injury site at one and four weeks post-transplantation in every twelfth section 
by persons blinded to the treatment groups. Numbers were averaged per experimental group. 
4.2.10 Measurement of Nervous Tissue Sparing 
Cresyl violet-stained sections of rats that survived for four weeks post-injection were used to 
determine the volume of spared tissue in the damaged spinal cord segment using the Cavalieri 
estimator function of StereoInvestigator® (MicroBrightField, Inc.) [235, 268]. Analysis was 
performed by personnel blinded to the experimental groups (n = 6/group). The Gundersen 
Coefficient of Error was <0.05 for all measurements. Spared tissue volume was expressed as a 
percentage of the volume (±SEM) of an equally-sized comparable uninjured spinal cord segment 
and averaged per experimental group. 
4.2.11 In Vitro Assessment of the Protective Effect of ESHU 
To assess ESHU's cell protective ability we kept BMSCs in vitro under oxidative stress, which is 
known to contribute to intraneural cell transplant loss [251, 252]. A total of 4 × 105 cells were 
incubated in 100 μl ESHU or PBS with 200 μM hydrogen peroxide (H2O2; Sigma–Aldrich) for 
24 h at 37 °C. Then, 100 μl Trypan Blue (Sigma–Aldrich) was added and viable (Trypan Blue-
negative) cells were quantified in a hematocytometer and expressed as a percentage of all 
counted cells. Results from nine samples from three independent experiments were averaged. In 
nine samples from three independent experiments, the average number of BMSCs expressing 
caspase 3, a marker for apoptosis, and 8-oxo-2′-deoxyguanosine (8-oxo-dG), a marker for DNA 
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damage, were determined (see above). Details on caspase 3 and 8-oxo-dG staining are described 
in 4.2.8. Immunocytochemistry. 
4.2.12 Quantification of ESHU’s Antioxidant Ability 
ESHU's ability to scavenge H2O2 relative to PBS was measured using a H2O2 quantification kit 
(National Diagnostics, Atlanta, GA, USA) which colorimetrically measures Xylenol Orange–
Ferric iron complex resulting from H2O2-mediated oxidation of ferrous iron. The linear standard 
curve of this assay is 15–100 ng/ml. We added 30 ng/ml H2O2 (Sigma–Aldrich) to ESHU or PBS 
which was kept in reagent buffer for 30 min following the manufacture's guidelines. Absorbance 
was measured (Victor 2V 1420; Perkin–Elmer, Waltham, MA, USA) and the values from three 
independent experiments were averaged. 
4.2.13 Statistical Analysis 
Two-tailed Student's T-test was used to determine differences in cell numbers in vivo and in vitro 
and in H2O2concentrations in vitro. One-way ANOVA with Tukey's post-hoc test was used to 
assess differences in macrophages and nervous tissue sparing. Repeated measures ANOVA with 
Tukey's post-hoc test determined differences in functional performances. Differences between 
groups were considered significant when p < 0.05. 
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4.3 RESULTS 
4.3.1 BMSC Transplant Survival 
We investigated whether ESHU protects transplanted BMSCs from death in damaged nervous 
tissue using a spinal cord contusion model. At 15 min post-injection, rounded BMSCs were 
present in the injury when mixed in either ESHU (Figure 17a) or PBS (Figure 17b). One week 
post-injection, in both groups many spindle-shaped cells were also found (Figure 17c, d). At 4 
and 6 weeks, hardly any cells could be found in or near the contusion site after injection of 
BMSCs in ESHU (Figure 17e) or in PBS (Figure 17f). The temporal morphological profile of 
the grafted cells is in accordance with earlier observations [243]. Also, GFAP staining (Figure 
17a-f) was similar as previously described [235, 243]. We found that 73 ± 17% (SEM; n = 6) of 
transplanted cells had survived in ESHU while 21 ± 8% (SEM; n = 6) survived in PBS (Figure 
17g), which represents a significant (p < 0.05) 3.5-fold increase in survival in ESHU compared 
with PBS. At four weeks post-injection, in both groups <1% of the cells has survived in the 
injury site. The data show that ESHU does not affect BMSC transplant morphology and protects 
against early death resulting in increased transplant presence at one week post-injection. 
 76 
 Figure 17. ESHU improves survival of BMSC transplants in a spinal cord contusion. 15 minutes after 
injection, transplanted cells (green) occupy most of the contusion regardless of whether they were suspended 
in ESHU (a) or PBS (b). Staining for GFAP (red) was used to outline the contusion. Transplanted cells 
(green) were mostly rounded in ESHU (inset a) and PBS (inset b). 1 week after injection, the transplant 
occupies only part of the contusion site but more so when suspended in ESHU (c) than PBS (d). Transplanted 
cells at this time point were mostly elongated with bipolar morphologies. 4 weeks after injection, hardly any 
cells were detected in the contusion in either group. Similar results were observed after 6 weeks (not shown). 
(g) More transplanted cells survive in the contusion site 1 week after injection when suspended in ESHU than 
PBS. Survival rate was measured against total number of injected cells. Error bars in graph display standard 
error of the mean (SEM). Asterisk = p<0.05. Bar in a = 350 µm in a-d and 30 µm in insets.  
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4.3.2 Effect of BMSC Transplant Survival on Neuroprotection 
Because BMSC transplant survival is associated with neuroprotection [243] we assessed whether 
ESHU-promoted transplant survival rendered enhanced tissue sparing (Figure 18a-d). The 
results demonstrated that the volume of spared tissue in rats with the transplant in ESHU is 66% 
larger (p < 0.05; n = 6/group) than in rats with the transplant in PBS at four weeks post-
transplantation (Figure 18e). ESHU only had no effect on spared tissue volume in the damaged 
area (Figure 18e). The data suggest that increased survival of intraneural BMSC transplants 
early after injection enhances neuroprotection of nervous tissue. 
 
Figure 18. ESHU augments neuroprotection by BMSC transplants in the contused spinal cord. 
Damage and loss of nervous tissue were observed 4 weeks after a BMSC transplant in ESHU (a) or PBS (b), 
or ESHU (c) or PBS (d) alone into the contused spinal cord. (e) Spared tissue volume was larger with the 
transplant in ESHU compared with all other groups. Error bars represent SEM, and asterisks = p<0.05. Bar 
in = 600 µm in a-d.  
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4.3.3 Effect of BMSC Transplant Survival on Motor Recovery 
After spinal cord contusion, motor performance depends in part on the amount of nervous tissue 
at the injury site [235]. We examined whether augmented neuroprotection by BMSC transplants 
with ESHU-enhanced survival affected motor function recovery. We found that rats with the 
transplant in ESHU performed significantly (p < 0.05; n = 10/group) better in overground 
walking than rats with BMSC in PBS at 4–6 weeks post-injury (Figure 19a). Rats with BMSC in 
ESHU performed better than rats with ESHU or PBS alone at 1–6 weeks post-injury and rats 
with BMSCs in PBS walked better overground than rats with ESHU or PBS alone only at 1–3 
weeks post-injury (Figure 19a). At 6 weeks, rats with BMSCs in ESHU showed consistent 
(>95%) weight-supported plantar steps with frontlimb–hindlimb coordination. The control 
transplanted rats were less consistent (50–95%) making such steps, whereas rats with ESHU or 
PBS only were less consistent and lacked frontlimb–hindlimb coordination. During the 4th–6th 
week after injection, overground walking was increased by 1.7 ± 0.4 points on the BBB scale in 
rats with the transplant in ESHU which was significantly (p < 0.05; n = 10/group) higher than the 
increase in the other groups (Figure 19b). Higher motor functions of the hindlimbs were 
significantly improved (p < 0.05; n = 10/group) by 74% in rats with BMSC in ESHU compared 
with BMSCs in PBS at 6 weeks post-injury (Figure 19c). Sensorimotor function was 
significantly increased (p < 0.05; n = 10/group) in rats with the transplant in ESHU compared 
with the other three groups at 6 weeks post-injury (Figure 19d). Rats receiving the transplant in 
PBS had significantly improved sensorimotor function compared with rats with ESHU or PBS 
alone (Figure 19d). 
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 Figure 19. ESHU leads to enhancement of motor function recovery by a BMSC transplant in the 
contused spinal cord. (a) Overground walking ability was significantly improved in rats with a BMSC 
transplant in ESHU compared with BMSCs in PBS 4-6 weeks post-injury. Rats with BMSC in ESHU 
performed better than rats with ESHU or PBS alone at 1-6 weeks post-injury. Rats with BMSCs in PBS 
walked better overground than rats with ESHU or PBS alone only at 1-3 weeks post-injury. (b) Improvement 
in overground walking ability during the 4th-6th week post-injury was significantly improved in rats with a 
transplant in ESHU compared with all over groups. (c) Improved higher motor function in rats with BMSCs 
in ESHU compared with PBS at 6 weeks post-injury. (d) Improved sensorimotor recovery in rats with the 
transplant in ESHU over all other groups and in rats with BMSCs in PBS over the control groups without 
BMSCs at 6 weeks post-injury. Error bars in bar graph display SEM. Asterisks signify p<0.05. Pound sign 
signifies p<0.05.  
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4.3.4 Inflammatory Response 
Macrophages invade damaged nervous tissue and contribute to cell death [247]. ESHU 
breakdown products could carry negative charges and so affect macrophage presence [269]. We 
tested the possible influence of macrophages on ESHU's protective capacity by assessing their 
presence in the injury after injection of BMSCs in ESHU (Figure 20a-c) or PBS (Figure 20d-f), 
or ESHU or PBS only. The results demonstrated similar macrophage presence between all 
groups at one (Figure 20g) and four (Figure 20h) weeks post-injection, suggesting that ESHU is 
non-immunogenic. The data indicate that macrophages are not implicated in ESHU-mediated 
transplant survival. 
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 Figure 20. ESHU does not affect the injury-induced macrophage response. Macrophages (ED-1+, 
red) were found in the contusion with transplanted BMSC (green) in ESHU (a-c) or PBS (d-f). (g) ESHU as a 
transplant matrix or alone did not affect the presence of macrophages in the contusion at one and four weeks 
after transplantation. Error bars display SEM. Bar in a = 15 µm in a-f.  
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4.3.5 Oxidative Stress-Mediated Cell Death In Vitro 
We tested whether ESHU protects BMSCs from H2O2-mediated death in vitro (Figure 21a) and 
found that survival was increased four-fold in ESHU (62 ± 6%, SEM; n = 9) compared with PBS 
(15 ± 2%, p < 0.05,n = 9; Figure 21b). ESHU resulted in an almost two-fold decrease in BMSCs 
positive for caspase 3 or 8-oxo-dG (p < 0.05, n = 9; Figure 21c). To explore ESHU's cell 
protective effects, we assessed its proficiency in scavenging H2O2. We found that ESHU 
decreased the amount of H2O2 by 10% (3 ng/ml) in 30 min compared with PBS (p < 0.05, n = 9; 
Figure 6d), suggesting ESHU-mediated oxidation of H2O2. The data show that ESHU scavenges 
H2O2 and protects against oxidative stress-mediated cell death. 
 
Figure 21. ESHU protects BMSCs in suspension and scavenges hydrogen peroxide in vitro. (a) 
Schematic representation of in vitro assay of ESHU’s ability to protect BMSCs from H2O2-induced death. (b) 
Cell survival from H2O2-induced oxidative stress is better in ESHU than PBS. (c) Fewer BMSCs positive for 
caspase 3 and 8-oxo-dG with ESHU (red) than with PBS (green). (d) ESHU scavenges H2O2 in PBS. Error 
bars in bar graphs display SEM. Asterisks represent p<0.05.  
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4.4 DISCUSSION 
We show that ESHU, a synthetic injectable reverse thermal gel, protects transplanted BMSCs 
from death thereby prolonging their presence in damaged nervous tissue and leading to enhanced 
tissue sparing accompanied by improved motor function recovery. Our study demonstrates that 
improved intraneural BMSC transplant survival enhances their effects on repair, which may have 
widespread impact on BMSC-based therapies for tissue repair. 
The inclusion of ESHU enhanced BMSC presence in a contusion in the adult rat spinal 
cord. This effect was transient possibly due to degradation of ESHU [193]. When mixed in 
culture medium, BMSC presence was significantly lower in the contusion site [243-246, 270]. 
Possibly ESHU retains BMSCs better in the contusion (i.e., the site of injection) compared with 
culture medium, resulting in the higher numbers. Previously we showed that about 2.4% of GFP-
expressing BMSCs in culture medium leaked or migrated away from a contusion [243]. 
Therefore, the present results suggest that ESHU protects transplants in the contused spinal cord 
tissue during the first week post-injection, which is a critical time period for BMSC-mediated 
neuroprotection [243]. 
The ESHU-mediated increase in BMSC survival in the contused spinal cord resulted in 
anatomical (tissue sparing) and functional (motor/sensorimotor) improvements. Spared tissue 
volume was not affected by ESHU alone, indicating that the neuroprotection was elicited by the 
increased survival of the transplant. Previously, we showed that the neuroprotective effects of 
BMSC transplants are greatest during the first week post-injury [243]. The current finding 
demonstrates that the efficacy of an intraspinal BMSC transplant to elicit neuroprotection 
depends on its degree of survival and that increased survival leads to increased spared tissue 
volumes. Neuroprotection by intraneural BMSC transplants is thought to result from paracrine 
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effects [239-242]. Our finding that increased transplant survival results in increased tissue 
sparing may imply that the magnitude of neuroprotection elicited by the transplants depends on 
the concentration and/or availability of secreted growth factors mediating paracrine actions. 
Overground walking and higher motor and sensorimotor functions of the paralyzed 
hindlimbs were further improved in rats that received BMSCs in ESHU. The improvements in 
overground walking were particularly evident during the second half of the 6-week period. It was 
demonstrated that BMSC transplant-mediated improvements in motor function recovery after 
spinal cord [232-235, 246] and brain [271-273] injury are correlated with the amount of spared 
nervous tissue [235, 274]. Thus, in our study, neuroprotection elicited by BMSC transplants with 
ESHU-increased survival likely contributes to the observed improved motor function recovery. 
At present the anatomical correlates underlying improved motor recovery are not completely 
known but may involve increased numbers of descending axons conducting the actual motor 
activity [235] and/or increased myelination providing better signal conduction [274, 275], which 
both could result from neuroprotection. 
In search of potential mechanisms underlying ESHU-mediated BMSC protection, we 
assessed macrophage presence in the contusion. Macrophages are naturally present in damaged 
nervous tissue and contribute to the death of neural and transplanted cells [244, 245, 247]. 
Oxidation of ESHU could lead to carboxylates whose negative charges might inhibit adhesion of 
macrophages [269] thereby limiting their contribution to cell death. We found that the number of 
macrophages in the contusion was similar with or without the presence of ESHU. BMSCs are 
hypoimmunogenic, lacking MHC class II and co-stimulatory molecules for effector T cell 
induction [276], and suppress T cell proliferation [277]; thus the adaptive immune response is 
unlikely to be largely involved in allogeneic BMSC death. Our data suggest that the protective 
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effects of ESHU result from direct effects on the transplant rather than indirect effects involving 
macrophages. 
Another possible mechanism underlying ESHU-promoted BMSC survival is 
antioxidation. Reactive oxygen species (ROS) accumulate rapidly in damaged nervous tissue, 
and induce oxidative stress, leading to cell death [248-252]. We used H2O2 to determine whether 
ESHU has the ability to scavenge ROS and thus mediate antioxidant effects. H2O2 is amply 
present in damaged nervous tissue [278]. We found that a 16% ESHU solution removed 3 ng 
H2O2 in a 30 min time period. Assuming continuous activity at 3 ng/30 min, ESHU removed 
∼20% of added H2O2 in our in vitro assay of ESHU's ability to protect BMSCs, which elicited a 
47% increase in their survival relative to PBS. The ability to scavenge ROS may be exerted 
through its urethane groups [253, 254]. Possibly ESHU's antioxidant effects may be increased 
with higher concentrations [279]. Our observations point at antioxidation as a potential 
mechanism of ESHU-promoted BMSC transplant survival. ROS are known to contribute to 
transplanted cell death [251, 252]. Future studies need to define molecular factors in ESHU's 
protective actions and whether the protection by ESHU in vivo is concentration-dependent. 
4.5 CONCLUSIONS 
We demonstrate that the reparative effects of a BMSC transplant are enhanced by promoting 
their survival. This finding critically impacts current and future BMSC-based therapies for the 
central nervous system. ESHU's ability to gel at body temperature allows for injection (i.e., 
minimally invasive) into closed injuries. Besides reducing oxidative stress and serving as a 
matrix for cells, ESHU can also be used to deliver drugs and/or functionalized with bioactive 
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molecules to affect targeted biological events. These benefits render ESHU an important 
candidate in future therapies for the traumatized or degenerated nervous system. Furthermore, 
because oxidative stress is part of many diseases where BMSCs can be effective, such as cardiac 
myopathy and peripheral arterial disease, ESHU may have wide therapeutic relevance. 
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5.0  INJECTABLE COACERVATE FOR GROWTH FACTOR DELIVERY TO THE 
CONTUSED SPINAL CORD 
5.1 INTRODUCTION 
The complex progression of events following traumatic spinal cord injury (SCI) poses a 
significant challenge for providing effective treatment. Cell death, disruption of local blood flow, 
inflammation, reactive oxygen species and myelin debris contribute to an inhibitory environment 
that severely limits the regenerative potential of the central nervous system (CNS) [1]. Many 
strategies such as cell transplantation and biomaterials-based scaffolds have been employed to 
engineer a favorable environment for neuronal repair; despite some promising results however, 
most have demonstrated limited success. Controlled drug delivery directly to the injured spinal 
cord is one promising strategy for promoting neural repair; however its efficacy is limited by the 
short half-life of free proteins in the body, the highly inflammatory environment which can 
neutralize administered therapies, and the need for an injectable, biodegradable and 
biocompatible delivery system that will release drugs slowly over time while simultaneously 
protecting their bioactivity.  
Here we explore a novel growth factor delivery system to deliver sonic hedgehog (Shh) 
to the injured spinal cord. The delivery system is composed of a synthetic polycation, 
poly(ethylene argininylaspartate diglyceride), or PEAD. The arginine moieties on the PEAD 
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backbone impart positive charge to the polymer, which enables it to bind heparin electrostatically 
[280]. When PEAD and heparin are combined they interact to form small sub-micron sized 
aggregates referred to as a “coacervate”. This system can deliver heparin-binding growth factors 
and morphogens with enhanced bioactivity [281, 282] and has been studied in the context of 
wound healing, cardiac repair, bone regeneration and therapeutic angiogenesis [283-286]. The 
attractiveness of the coacervate system lies in its injectability, the ability to deliver multiple 
growth factors, and its demonstrated ability to deliver growth factors with enhanced bioactivity 
[281].  
Because it is generally accepted that a combinatorial approach to treating SCI will likely 
yield the best results, we chose to deliver a pleiotropic molecule to the injured spinal cord using 
the coacervate system and investigate anatomical and functional outcomes. Shh is heavily 
involved in neural development, influencing motor neuron and oligodendrocyte specification, 
axon guidance, and neural precursor proliferation [287]. It has also been implicated in 
angiogenesis, blood-brain barrier homeostasis and proliferation of adult neural precursors in the 
subventricular zone of the brain [288-290]. In the more regenerative peripheral nervous system 
(PNS), Shh is upregulated in Schwann cells adjacent to the injured sciatic nerve, which results in 
subsequent expression of brain-derived neurotrophic factor (BDNF). Inhibition of Shh with 
cyclopamine suppressed BDNF expression and decreased motor neuron survival in lumbar spinal 
cord, which suggests a potential neuroprotective role of Shh in the PNS [291]. Interestingly, in 
non-mammalian vertebrates such as zebrafish who are capable of CNS regeneration, Shh is 
expressed at high levels throughout adulthood, and inhibiting its signaling following SCI impairs 
motor neuron regeneration [292]. Moreover, regenerating newt limbs express Shh, and inhibition 
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of Shh signaling with cyclopamine inhibits regeneration [293, 294]. This information suggests 
that the presence of Shh signaling is involved in successful regeneration.  
A handful of studies have discussed the potential for exogenous Shh administration to 
influence outcomes following CNS trauma. For example, Shh administration induces diffuse 
proliferation of nestin-positive precursors following SCI as well as ischemic stroke [295-297]. 
When transplanted in combination with oligodendrocyte precursors, substantial white matter 
sparing and functional recovery was observed [298]. Finally, delivery of Shh-loaded PLGA 
microspheres resulted in functional recovery, decreased glial scarring and proliferation of NG2-
positive cells following administration in both contusion and dorsal over-hemisection models of 
SCI in mice [299]. The precise mechanisms for the effects of Shh are unclear, though it is 
obvious that Shh is a promising candidate for CNS therapy. Therefore, we hypothesized that 
controlled Shh delivery from a heparin-based coacervate delivery system would improve 
outcomes after contusion in adult rats. The objective of this work was to evaluate the 
biocompatibility of the coacervate in the injured spinal cord, and assess the effectiveness of Shh 
in promoting repair.   
5.2 MATERIALS AND METHODS 
5.2.1 Coacervate Preparation 
The cationic polymer, poly(ethylene argininylaspartate diglyceride) (PEAD), was synthesized as 
previously described [280]. PEAD and clinical-grade heparin (Scientific Protein Labs, 
Waunakee, WI) were each dissolved in 0.9% saline, and sterilized via filtration through 0.22 µm 
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filters. To prepare the coacervate, heparin was first complexed with Shh (Peprotech) then PEAD 
was added. Self-assembly of the PEAD and heparin:Shh complexes resulted in immediate 
precipitation to form the coacervate. Solutions were prepared at a final Shh concentration of 100 
ng/µl. For controls, heparin was directly complexed with PEAD without the addition of Shh. 
5.2.2 Spinal Cord Contusion Model  
All animal experiments were conducted in compliance with protocols approved by the 
Institutional Animal Care and Use Committee at the University of Pittsburgh, with strict 
adherence to guidelines of the National Institutes of Health and United States Department of 
Agriculture. Female Sprague Dawley rats (225-250g, n=10/group; Charles River Laboratory, 
Wilmington, MA, USA) were anesthetized via intraperitoneal injection of ketamine (60 mg/kg 
Butlerschein, Dublin, OH, USA) and dexdomitor (0.5 mg/kg, Pfizer, New York, NY, USA). 
Following laminectomy, an Infinite Horizon impactor (Precision Systems and Instrumentation, 
LLC, Versailles, KY, USA ) was used to generate a 200 kDyne contusion injury at the tenth 
thoracic segment of the spinal cord. The injury was then rinsed with sterile 0.9% saline 
containing 0.1% gentamicin (VWR, Radnor, PA, USA), the muscles were sutured and the skin 
closed with Michel wound clips (Fine Science Tools, Foster City, CA, USA). Three days post-
injury, animals were sedated for a second time, the injury site was exposed and animals were 
injected with 5 µl of one of four treatments: PEAD:Heparin:Shh, PEAD:Heparin, Shh only, or 
PBS only. For groups receiving Shh, the total administered dose was 500 ng.  
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5.2.3 Post-Surgical Care 
Antisedan (1.5 mg/kg; Pfizer, New York, NY, USA) was injected subcutaneously to wake the 
animals following both procedures. Intramuscular administration of gentamicin (6 mg/kg; VWR, 
Radnor, PA, USA), was administered for 7 days following injury, and subcutaneous 
administration of Rimadyl (5 mg/kg; Pfizer, New York, NY, USA) and Ringer’s solution (5 ml; 
Butlerschein, Dublin, OH, USA) were administered for 6 days post-injury. Bladders were 
manually expressed twice daily until the ability to urinate was regained (approximately 2 weeks 
post-injury). 
5.2.4 Motor Function Assessment  
5.2.4.1 BBB 
Overground walking ability of the animals was assessed using the Basso, Beattie and 
Bresnahan (BBB) open field test [262]. Animals were assessed at 1, 3, 7, 14, 21, 28, 35 and 42 
days post-injury. Experimenters blinded to treatment groups observed the animals for 4 minutes 
and assigned a score between 0 and 21, signifying the hindlimb locomotor capability of the 
animal. 
5.2.4.2 Horizontal Ladder Walk 
Sensorimotor function was assessed using the horizontal ladder test. Rats were recorded 
walking across a ladder with irregularly-spaced rungs, and slips of the foot up to the ankle 
(small) and whole leg (large) were counted and expressed as a percentage of the total number of 
steps taken. Three runs were analyzed per animal. 
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5.2.4.3 Gait Analysis 
The DigiGait Analysis System (MouseSpecifics, Boston, MA, USA) was used to analyze 
specific parameters of hindlimb locomotion before and after injury. The DigiGait system consists 
of a clear treadmill with a camera located underneath which records and digitizes the animal’s 
footprints. Animals were acclimated to the treadmill for four days prior to taking baseline (pre-
injury) and endpoint (6 weeks post-injury) video recordings at a speed of 20 cm/s. The videos 
were then analyzed for a number of gait indices such as paw area, paw angle, stride length and 
coordination.  6 week data were compared to baselines and values averaged per experimental 
group. 
5.2.5 Histological Analysis 
Six weeks post-injury, rats were anesthetized, then transcardially perfused with 300 mL PBS, 
followed by 400 mL 4% paraformaldehyde (Sigma-Aldrich, Allentown, PA, USA) in PBS. 
Spinal cords were dissected and post-fixed in 4% paraformaldehyde overnight, followed by 
cryoprotection in 30% sucrose for at least 48h. A spinal cord segment measuring 12 mm centered 
on the lesion was cut into serial sections at a thickness of 14 µm. Histological stains included 
cresyl violet for general morphology and tissue sparing analysis. Immunohistochemical stains 
included GFAP (1:400, DAKO), ED1 (1:250, Millipore), 5-HT (1:2000, Immunostar), RT-97 
(1:200, DSHB), and Nestin (1:100, BD Biosciences). Briefly, sections were blocked for 1h at 
room temperature with 10% normal goat serum (NGS) with 0.1% Triton, then incubated 
overnight in 1° antibody solutions diluted in 2% NGS with 0.1% Triton. After washing, samples 
were incubated in 2° solutions (goat anti-mouse 488 or goat anti-rabbit 594, 1:200, Invitrogen) 
for 2h at room temperature, washed and counter-stained with DAPI, then coverslipped.  
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5.2.6 Quantitative Immunofluorescence Analysis 
Images were analyzed using Nikon NIS Elements software. For macrophage quantification, the 
number of ED1 positive cells was quantified on large image composites of the entire lesion and 
expressed as a function of the tissue area. GFAP intensity was assessed on images taken rostral, 
caudal, and at the lesion epicenter, and total intensity was considered to be the average intensity 
of all regions. 5HT and RT97 were quantified similarly, and the total amount of positive fiber 
staining was expressed as a function of the tissue area.  
5.2.7 Statistical Analysis 
Data are expressed as mean ± standard error of the mean (SEM). Statistical analyses for endpoint 
outcomes such as Digigait, tissue sparing and immunohistochemistry were performed using one-
way ANOVA with Fisher pairwise comparisons when significance (p<0.05) was indicated. 
Repeated measures analysis was used for time-dependent studies (BBB, horizontal ladder walk) 
with Fisher pairwise comparisons when significance was indicated. All data were analyzed using 
Minitab 17 software.  
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5.3 RESULTS AND DISCUSSION 
5.3.1 Biocompatibility of PEAD in the Injured Spinal Cord 
Because PEAD is untested in the injured spinal cord, we sought to assess its biocompatibility by 
quantifying the inflammatory response and the extent of glial scarring. Following traumatic 
injury, there is a large influx of macrophages to the spinal cord both at the lesion epicenter and in 
more distant regions of the cord which is sustained for several weeks [300]. Introduction of a 
foreign material may worsen this response; therefore the density of ED1+ macrophages was 
quantified within the lesion. The macrophage density was similar in all experimental groups 
tested (p>0.05), suggesting that PEAD injection does not exacerbate inflammation (Figure 22A, 
D). Similarly, analysis of glial fibrillary acidic protein (GFAP) revealed that PEAD injection did 
not increase glial scarring (Figure 22B, C, D). Glial scar formation is part of the highly complex 
cascade of reactive processes which occurs following injury and serves to preserve still healthy 
tissue from injury progression. Many of the cell types that compose the scar, such as astrocytes 
and meningeal fibroblasts, produce inhibitory molecules which prevent axon regeneration and 
therefore it is critical that an increase in scar formation is not observed [301]. Additionally, the 
Shh-coacervate group saw a significant reduction in total glial scar formation as well as scarring 
at the lesion epicenter compared to PBS and empty coacervate groups. Free Shh also had 
significantly less scarring compared to empty coacervate groups at the lesion epicenter. This data 
suggests that Shh may play a role in reducing astrocyte activation and subsequent scar formation. 
While the effects of Shh administration on glial scar formation have not been explicitly studied, 
it has been reported that hedgehog pathway activation in astrocytes can alter their phenotypic 
behavior following injury [302]. Specifically, Shh induces phenotypic plasticity in activated 
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astrocytes both in vitro and in vivo following middle cerebral artery occlusion and stab wound 
injuries in the brain. When isolated and cultured in vitro, these cells can differentiate into 
neurons, oligodendrocytes and astrocytes with the proper cues. It is possible that exogenous Shh 
administration alters the typical behavior of the activated astrocytes and thus reduces their 
contribution to scar formation, though more exhaustive mechanistic studies would need to be 
performed to confirm this hypothesis.    
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 Figure 22. Effect of PEAD injection on the inflammatory response. PEAD does not increase the 
macrophage density at the lesion epicenter (A, D). Glial scarring, as measured by the intensity of GFAP 
staining, was also not different in groups receiving the coacervate compared to PBS controls. The intensity of 
the entire glial scar was quantified (B) as well as at the lesion epicenter, where presumably scarring would be 
the most prominent (C). In both cases, animals receiving the Shh coacervate had a significant (p<0.05) 
reduction in GFAP intensity compared to PBS and empty coacervate groups, indicating a possible effect of 
Shh delivery on scar formation. (Scale bar = 500 µm)   
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5.3.2 Effect of Controlled Shh Delivery on Nervous Tissue Sparing 
It has previously been reported that intrathecal Shh administration results in tissue sparing 
following ischemic stroke in rats, presumably due to the recruitment of nestin-positive progenitor 
cells which may exert a neuroprotective effect [295]. Therefore, the volume of spared nervous 
tissue was quantified stereologically to determine whether local Shh delivery will have a similar 
effect in spinal cord injured animals. Figure 23 shows the nervous tissue volume expressed as a 
percentage of healthy spinal cord tissue. The Shh coacervate group had the largest volume of 
spared tissue (32.23 ± 10.08% compared to 28.78 ± 9.07% in PBS, 26.31 ± 6.24% in empty 
coacervate and 28.47 ± 9.18% in free Shh groups) suggesting a potential effect of Shh delivery 
on tissue preservation, though the differences are not statistically significant. Future Shh dose 
optimization may result in more substantial tissue sparing compared to controls.  
 
Figure 23. Effect of Shh administration on nervous tissue sparing. Nervous tissue sparing was not 
statistically significant between experimental groups; however Shh-coacervate treatment did result in the 
largest percentage of tissue sparing. 
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5.3.3 Neuronal Fiber Density 
To assess whether controlled Shh delivery had an effect on neural cell populations or axon 
growth beyond the lesion we quantified neurofilament presence with the antibody RT97, and 
serotonergic fibers with 5HT. The relative density of positive staining was determined both 
rostral and caudal to the lesion and results are shown in Figure 24. There appear to be trends 
towards increased 5HT and RT97 staining in Shh coacervate groups, especially rostral to the 
lesion. This suggests that Shh may be playing a role in limiting neuronal dieback and preserving 
neuronal viability. These data are in agreement with previously reported results that found Shh 
administration increased the length of serotonergic fibers [299]. 
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 Figure 24. Density of axons and serotonergic fibers rostral and caudal to the lesion. The amount of 
positive neurofilament (A) and sorotonergic fiber (B) staining was determined by calculating the area of 
positive staining as a fraction of total tissue area.  
5.3.4 Motor Function Outcomes 
The BBB test was performed weekly throughout the study period. In order to account for 
variability between animals, BBB scores for each animal were normalized by their 1 day post-
injury values (Figure 25). The free Shh group has an early increase in BBB score that plateaus at 
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around 28 days, while the Shh-coacervate animals exhibited slowly improving scores throughout 
the study period. Perhaps this suggests an early improvement in motor function following 
exposure to a large dose of Shh whose effects wear off after a few weeks, whereas controlled 
release of Shh causes a steady, gradual improvement. Statistically, there were no differences 
between free Shh, Shh-coacervate groups and PBS controls; however, the empty coacervate 
group had significantly lower scores than the other three groups when the effect of day was 
removed.   
 
Figure 25. BBB results. Free Shh groups performed well early, whereas Shh-coacervate groups had 
steadily increasing BBB scores throughout the study.  
 
Similar phenomena could be observed in the horizontal ladder results. Looking at the 
improvement in slips over time (Figure 26) shows that Shh-coacervate animals had the highest 
reduction in the number of slips made from 2 to 4 weeks post injury, 4 to 6 weeks post injury, as 
well as 2 to 6 weeks post injury. However the high variability observed between animals for this 
particular assessment means that none of these results were statistically significant.  
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 Figure 26. Improvement in hindlimb stepping over time. Shh-coacervate groups had the largest 
decrease in the number of slips made over the time course of the study period. This indicates that 
improvements in sensorimotor function were the largest in the controlled delivery groups. 
 
Finally, Digigait analysis indicated slight differences between experimental groups 
(Figure 27). 100% of animals in free Shh and Shh-coacervate groups were physically capable of 
walking on the treadmill at a speed of 20 cm/s. However, in the empty coacervate and PBS 
control groups, 80% and 90% of animals respectively were unable to walk and therefore data 
could not be obtained. This suggests that animals receiving Shh performed better at higher 
walking speeds than animals receiving control injections. Additionally, stride length was 
measured and compared to that of healthy animals. Shh-coacervate stride length was the only 
group whose stride length was not significantly different from healthy animals. Injured animals 
had a longer stride length as it takes more time for them to lift and swing the hindlimb through to 
the top of the step; therefore, animals receiving the Shh-coacervate had regained a stride length 
comparable to healthy animals. Additionally, Shh-coacervate and free Shh animals had a 
significantly lower paw angle than PBS or empty coacervate groups, though these values were 
still significantly larger than the paw angle of healthy animals. The increased paw angle is a 
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result of attempted stability following injury. Hindlimb weakness prevents the animals from 
adopting a normal stance and thus their paws turn out in order to provide more stability. The 
significant reduction seen in Shh groups suggests an increased stability in the overground 
walking ability of these animals.  
 
Figure 27. Gait analysis reveals slight improvements in overground walking ability of Shh-coacervate 
animals. In control groups, three animals were unable to walk at the recording speed of 20 cm/s. All animals 
in free Shh and Shh-coacervate groups were capable of walking (A). The stride length of Shh-coacervate 
animals was not significantly different than healthy animals, suggesting an improvement in stepping (B). The 
paw angle of free Shh and Shh-coacervate animals was significantly less than in controls, suggesting an 
improved stability when stepping, though the paw angles were still significantly different than in uninjured 
controls (C).  
 Slight trends toward improved functional recovery, axon density and tissue 
sparing in Shh-coacervate groups can be potentially be explained by a few factors. The first is 
that dose optimization was not performed in this study; because little work has been done in 
exploring exogenous Shh administration to the injured spinal cord, we chose 500ng based on 
what available information there was, combined with the dose that was demonstrated to elicit a 
significant response in cardiac cells in vitro [284]. Additionally, it is possible that the 3-day 
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delayed injection, while more clinically relevant, is unsuitable for growth factor administration. 
The high level of inflammation at that time period may have speeded up Shh release from the 
coacervate and limited its controlled release capabilities. In the future, dose and treatment time 
optimization may futher enhance the efficacy of this system in treating contusive SCI.  
5.4 CONCLUSIONS 
The present work demonstrated the utility of an injectable, affinity-based growth factor delivery 
system to the injured spinal cord. PEAD is compatible with CNS tissues and does not negatively 
impact the typical course of injury progression. Controlled release of sonic hedgehog resulted in 
decreased glial scarring, and may potentially be involved in neuronal survival and nervous tissue 
sparing. Future work will focus on dosage optimization and combinatorial approaches, such as 
multiple growth factor delivery, or cell transplantation combined with growth factors to sustain 
transplant survival.  
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6.0  FINAL SUMMARY  
Efficient and effective treatment of CNS injury and disease remains a significant challenge due 
to the intricate structure and function of the CNS, barriers to effective diffusion and unfavorable 
environments for regeneration. Achieving desired release characteristics while simultaneously 
protecting the activity of therapeutic biomolecules is critical for the success of controlled drug 
delivery. The present work describes the formulation, characterization and in vivo evaluation of 
two novel injectable drug delivery systems that are ideally suited for CNS applications. The 
biomaterials systems discussed herein can be utilized as minimally invasive neural therapeutics 
either alone or in combination with other strategies to enhance clinical outcomes. This work lays 
the foundation for the continued use of these platform technologies for a myriad of applications 
that span several tissue and organ systems.  
6.1 OCULAR DRUG DELIVERY USING REVERSE THERMAL GELS – MAJOR 
FINDINGS, LIMITATIONS AND FUTURE WORK 
In the eye, we studied the viability of an bevacizumab-containing reverse thermal gel system for 
intravitreal drug delivery. The major findings of this work are: 
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• ESHU gels are compatible with ocular cell types in vitro, and cause minimal cell 
death. Compared to commonly-used clinical materials such as silicone, ESHU is 
relatively non-toxic. This indicates that ESHU should display good 
biocompatibility in the eye.  
• When dissolved in bevacizumab solutions, ESHU gels form an anti-angiogenic 
drug delivery system that sustains bevacizumab release for over 17 weeks in vitro.  
• ESHU-bevacizumab delivery systems are easily injectable through 31G needles 
and instantaneously form spherical hydrogels upon injection to rabbit eyes.  
• ESHU is biocompatible in the eye – intraocular pressure and retinal integrity are 
unaffected by the presence of the gels and there is little observed inflammatory 
response. 
• Bevacizumab release from hydrogels is sustained for over 9 weeks in vivo at 
levels approximately 4 times higher than drug alone, indicating that ESHU 
delivery systems can prolong bevacizumab presence in the eye as hypothesized. 
These findings demonstrate the promise of reverse thermal gels for intravitreal drug 
delivery. Such a strategy has distinct advantages, such as direct exposure of posterior segment 
tissues to the released drug, minimally invasive administration, and no need for surgical removal 
of the delivery system. There are two major limitations to this work which are currently being 
addressed and will be reported in future studies: 
• Confirmation of maintained bioactivity of the released bevacizumab over time, 
both in vitro and in vivo. 
• Optimization of bevacizumab degradation time with drug release. 
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The released bevacizumab was detected using a VEGF ELISA, which indicates that 
detected drug is still capable of binding its target, providing evidence that bioactivity is 
maintained. However, limited stability of bevacizumab posed significant complications when 
performing assays to assess bioactivity. Due to a lack of reliable, well-controlled animal models 
for choroidal neovascularization and because bevacizumab is a humanized antibody [228], in 
vivo efficacy of the ESHU delivery system was not assessed in rabbits. Future work will focus 
on testing this delivery system in an actual animal model of CNV. Two experimental models are 
currently being considered: the first is a transgenic mouse that is engineered to overexpress 
humanized VEGF in the retina [303], and the second is a non-human primate model of CNV 
induced by laser photocoagulation [304].  
Finally, our in vivo work showed that all drug was released from the hydrogels several 
weeks before the gels had degraded. Because the eye is considered immune-privileged, there are 
few enzymatic or cellular factors affecting degradation of the gel. Therefore, hydrolysis is the 
principle degradation mechanism, which is known to be slow in degrading polyurethanes [305]. 
A significant challenge in translating this technology will be successful degradation of the gel at 
a rate that is in line with drug release and, therefore, injection frequency. Therefore, the chemical 
structure of ESHU is currently being adjusted by the introduction of polyester bonds in order to 
increase the rate of hydrolytic degradation of gels in vivo.    
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6.2 IMPROVED TRANSPLANT SURVIVAL USING REVERSE THERMAL GELS 
FOR TREATMENT OF SPINAL CORD INJURY – MAJOR FINDINGS, LIMITATIONS 
AND FUTURE WORK 
To demonstrate the versatility of ESHU as a platform delivery technology, we assessed its effect 
on transplant survival in spinal cord injured rats. Major findings from this work include: 
• ESHU protects transplanted BMSCs from oxidative stress-induced death in vitro. 
Physical protection of the cells as well as oxidation of urethane bonds in the gel 
by reactive oxygen species are two potential protective mechanisms behind this 
effect.  
• This protective effect is translated in vivo, where BMSCs transplanted in ESHU 
had 3.5-fold increased survival 1 week post-injury. Long term (28d) survival of 
the cells, however, was not observed. 
• Increased cell survival in the first week after injury was associated with a 66% 
increase in nervous tissue sparing and enhanced hindlimb motor and sensorimotor 
recovery.   
The most significant finding of this work is that the reparative potential of transplanted 
cells can be directly linked to their survival – a long-hypothesized theory that had not previously 
been demonstrated. The most significant limitation of this work is a lack of precise 
understanding of the mechanisms behind which BMSC transplants promote repair and the major 
contributors to their fate. Though paracrine effects are thought to play a role, a more precise 
understanding of the mechanisms of BMSC-promoted repair will help drive the evolution of new 
transplant strategies. Even a small, one week increase in transplant survival resulted in 
significant functional and anatomical improvement. Future work should include further 
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enhancement of BMSC survival in the injured spinal cord, either by co-administration of 
survival-promoting factors, or by improved protection strategies. 
6.3 COACERVATE-BASED PROTEIN DELIVERY TO THE INJURED SPINAL 
CORD – MAJOR FINDINGS, LIMITATIONS AND FUTURE WORK 
The final chapter of this dissertation discusses the safety and efficacy of a coacervate-based 
growth factor delivery system to treat SCI. Because we recognize the eventual need for a 
combinatorial strategy for effective treatment of SCI, we wished to assess the feasibility of this 
delivery system, with the ultimate goal of utilizing it in combination with other treatment 
strategies. We chose to study sonic hedgehog protein, due to its well-known pleiotropic effects in 
the CNS and throughout the body. Major findings of this study are: 
• The PEAD coacervate is safe to use in the spinal cord; it does not exacerbate the 
inflammatory response following injury, nor does it increase glial scar formation.  
• Though the effects of controlled Shh delivery are inconclusive, slight 
improvements in tissue sparing, serotonergic fiber density and overground 
walking ability suggest that Shh administration does have an effect in the injured 
spinal cord that needs to be further evaluated.  
These findings demonstrate that the PEAD delivery system is a viable option for delivery 
of heparin-binding molecules to the spinal cord; however the inconclusive functional and 
anatomical results suggest that it will be best-suited for combinatorial treatment strategies. The 
major limitations of this work include: 
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• A lack of information about the effects of Shh administration to the injured spinal 
cord – a handful of reports exist that argue Shh could be beneficial, however dose 
optimization must be performed in order to maximize its therapeutic potential. 
• The time course of injury progression and treatment administration is critical for 
maximizing outcomes. A 3-day delayed injection of the PEAD-Shh delivery 
system may be sub-optimal. Evaluation of the best treatment time is necessary. 
Future work will focus on dose and intervention time optimization, as well as maximizing 
therapeutic outcomes by delivering multiple growth factors, further sustaining Shh release by 
utilizing the ESHU gel, or co-transplantation with BMSCs or other progenitor transplants.  
6.4 OVERALL CONCLUSIONS 
In summary, this work sets the foundation for easily implantable biomaterials-based treatment 
systems for CNS repair. These materials are platform technologies that can be utilized to deliver 
most types of drugs, biomolecules, and cells to promote repair and slow disease progression.  
The complexity of CNS injury and disease in many cases will necessitate multi-faceted strategies 
and the biomaterials described in this work are ideally designed for inclusion in such an 
approach. 
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APPENDIX A 
DETAILED ANALYSIS OF BEVACIZUMAB CONCENTRATIONS 
Methods: The observed concentrations were modeled using a first order compartment model for 
the 0.25 power of the bevacizumab concentration y(t):  
 
where x denotes the time in days, T denotes the treatment (coded 0 for bevacizumab and 1 for 
ESHU-bevacizumab) ϕe0 denotes the natural logarithm of the elimination rate constant for 
treatment A, ϕe1 the difference in the elimination rate constant between treatment EA and A, ϕa0 
denotes the natural logarithm of the absorption rate constant for treatment A, ϕa1 the difference in 
the elimination rate constant between treatment EA and A, ϕc0 denotes the natural logarithm of 
the absorption rate constant for treatment A, ϕc1 the difference in the clearance rate constant 
between treatment EA and A, a1i is a random effect for the absorption rate difference, and ϵ is a 
random error. 
Raising the bevacizumab concentration to the 0.25 power (taking the 4th root) was 
necessary to ensure homoskedasticity (constant variance) of the random errors (ϵ) and to 
guarantee convergence to the maximum likelihood parameter estimates for the nonlinear mixed 
effects model. This transformation was used instead of a logarithmic transformation because 
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several measured concentrations were recorded as zeroes. The effect of taking the 4th root is 
otherwise similar to the use of a logarithmic transformation. 
Results: Bevacizumab and ESHU-bevacizumab treatments had similar elimination rate 
constants so the model was refitted with ϕe1 constrained to zero. With only seven eyes, the 
random effects were not well estimated. The fixed effects, however, were well estimated as 
shown in Tables S1 and S2. Figure S1 compares the difference in effect for the treatments. For 
the fixed effects estimates (Table S1) and the corresponding fixed effects 95% confidence 
intervals (Table S2), the rate constants for the bevacizumab group are statistically significant 
(their confidence intervals exclude 0), and the differences with ESHU-bevacizumab treatment 
are statistically significant (their confidence intervals exclude 0). The widths of the confidence 
intervals (and correspondingly, the standard errors and t-statistics) indicate that the clearance rate 
constant between bevacizumab and ESHU-bevacizumab treatments, and the elimination rate 
constant for bevacizumab treatment were the most precisely estimated parameters (that is, their 
confidence intervals were narrow, their standard errors small relative to the parameter estimate, 
and consequently their t-statistics were very large). 
Table A1: Fixed effects parameter estimates for the fourth root of bevacizumab concentrations based on 
the fitted nonlinear mixed effects model. 
 
Model 
Parameter 
Estimate Standard 
Error 
Degrees of 
Freedom 
t-statistic P 
ϕe0 -3.232 0.046 66 -69.637 <0.0001 
ϕa0 0.911 0.290 66 3.145 0.0025 
ϕa1 -0.957 0.297 66 -3.216 0.0020 
ϕc0 -4.187 0.042 66 -99.503 <0.0001 
ϕc1 -0.216 0.040 66 -5.389 <0.0001 
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Table A2: 95% confidence intervals for fixed effect model parameters. 
 
Model Parameter Lower Bound Estimate Upper Bound 
ϕe0 -3.322 -3.232 -3.143 
ϕa0 0.352 0.911 1.469 
ϕa1 -1.531 -0.957 -0.382 
ϕc0 -4.268 -4.187 -4.106 
ϕc1 -0.294 -0.216 -0.139 
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